- Approval Id
- f4bc4a33d64b24f0
- Drug Approval Emc Name
- Remifentanil 5 mg powder for concentrate for solution for injection/infusion
- Drug Name
- Remifentanil 5 mg powder for concentrate for solution for injection/infusion
- Company Name
- hameln pharma ltd
- Company Address
- Nexus, Gloucester Business Park, Gloucester, GL3 4AG, UK
- Company Website
- https://www.hameln-pharma.com
- Company Telephone
- +44 (0)1452 621 661
- Company Medical Info Email
- drug.safety@hameln-pharma.co.uk
- Atc Code
- N01AH06
- Legal Category
- Prescription only medicine
- Authorisation Holder
- hameln pharma ltd
Nexus, Gloucester Business Park
Gloucester, GL3 4AG
United Kingdom
- Authorisation Number
- PL 01502/0118
- Authorisation Date
- 04/10/2022
- Instruction Authorisation Holder
- hameln pharma ltd
Nexus, Gloucester Business Park
Gloucester, GL3 4AG
United Kingdom
- Instruction Authorisation Number
- PL 01502/0118
- Instruction Authorisation Date
- 04/10/2022
- Instruction Composition
- One vial contains 5 mg remifentanil (as remifentanil hydrochloride).
Each 1 ml of solution for injection/infusion contains 5 mg remifentanil when reconstituted as directed.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Powder for concentrate for solution for injection/infusion
White to off-white or yellowish, compact powder
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Remifentanil is indicated as an analgesic for use during induction and/or maintenance of general anaesthesia under close supervision.
Remifentanil is indicated for provision of analgesia in mechanically ventilated intensive care patients 18 years of age and over.4.2 Posology and method of administration
\*\*Remifentanil should only be administered in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of anaesthetics and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.\*\*
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with remifentanil in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
\*\*Posology\*\*
\*\*\*\*4.2.1 General Anaesthesia\*\*\*\*
The administration of remifentanil must be individualised based on the patient's response.
\*\*4.2.1.1 Adults\*\*
\*\*\*Administration by Manually Controlled Infusion (MCI)\*\*\*
\*Table 1: Dosing Guidelines for Adults\*
| | | | |
| --- | --- | --- | --- |
| | \*\*REMIFENTANIL BOLUS INJECTION (micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION (micrograms/kg/min)\*\* | |
| \*\*Starting\*\* \*\*Rate\*\* | \*\*Range\*\* | |
| \*\*Induction of anaesthesia\*\* | | | |
| 1 (given over not less than 30 sec.) | 0.5 to 1 | - | |
| \*\*Concomitant anaesthetic\*\* | \*\*Maintenance of anaesthesia in ventilated patients\*\* | | | |
| • Nitrous oxide (66 %) | 0.5 to 1 | 0.4 | 0.1 to 2 | |
| • Isoflurane (starting dose 0.5 MAC) | 0.5 to 1 | 0.25 | 0.05 to 2 | |
| • Propofol (Starting dose 100 micrograms/kg/min) | 0.5 to 1 | 0.25 | 0.05 to 2 | |
When given by bolus injection at induction remifentanil should be administered over not less than 30 seconds.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic medicinal products required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects of remifentanil (hypotension and bradycardia).
No data are available for dose recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil.
\*Induction of anaesthesia\*
Remifentanil should be administered with a standard dose of hypnotic, such as propofol, thiopentone, or isoflurane, for the induction of anaesthesia. Administering remifentanil after a hypnotic will reduce the incidence of muscle rigidity. Remifentanil can be administered at an infusion rate of 0.5 to 1 micrograms/kg/min, with or without an initial bolus injection of 1 micrograms/kg given over not less than 30 seconds. If endotracheal intubation is to occur more than 8 to 10 minutes after the start of the infusion of remifentanil, then a bolus injection is not necessary.
\*Maintenance of anaesthesia in ventilated patients\*
After endotracheal intubation, the infusion rate of remifentanil should be decreased, according to anaesthetic technique, as indicated in the above table. Due to the fast onset and short duration of action of remifentanil, the rate of administration during anaesthesia can be titrated upward in 25 % to 100 % increments or downward in 25 % to 50 % decrements, every 2 to 5 minutes to attain the desired level of μ-opioid response. In response to light anaesthesia, supplemental bolus injections may be administered every 2 to 5 minutes.
\*Anaesthesia in spontaneously breathing anaesthetised patients with a secured airway (e.g. laryngeal mask anaesthesia)\*
In spontaneously breathing anaesthetised patients with a secured airway respiratory depression is likely to occur. Therefore attention must be given to respiratory effects possibly combined with muscular rigidity. Special care is needed to adjust the dose to the patient requirements and ventilatory support may be required. Adequate facilities should be available for monitoring of patients administered remifentanil. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression (intubation equipment must be available) and/or muscle rigidity (for more information see section 4.4).
The recommended starting infusion rate for supplemental analgesia in spontaneously breathing anaesthetised patients is 0.04 micrograms/kg/min with titration to effect. A range of infusion rates from 0.025 to 0.1 micrograms/kg/min has been studied.
Bolus injections are not recommended in spontaneously breathing anaesthetised patients.
\*Concomitant medicinal products\*
Remifentanil decreases the amounts or doses of inhalational anaesthetics, hypnotics and benzodiazepines required for anaesthesia (see section 4.5).
Doses of the following medicinal products used in anaesthesia have been reduced by up to 75 % when used concurrently with remifentanil: isoflurane, thiopentone, propofol, midazolam and temazepam.
\*Guidelines for discontinuation in the immediate postoperative period\*
Due to the very rapid offset of action of remifentanil no residual opioid activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of post-operative care.
If the longer acting analgesic has not reached the appropriate effect before the end of surgery, the administration of remifentanil may need to be continued to maintain analgesia during immediate post-operative period until longer acting analgesic has reached the maximum effect.
It is recommended that patients should be closely monitored post-operatively for pain, hypotension and bradycardia.
Further information about the administration in mechanically ventilated intensive care patients is given in section 4.2.3.
In spontaneously breathing patients the initial infusion rate of remifentanil may be decreased to 0.1 micrograms/kg/min and thereafter can be increased or decreased every 5 min in steps of 0.025 micrograms/kg/min to balance the extent of analgesia against the degree of respiratory depression.
In spontaneously breathing patients bolus doses for analgesia are not recommended during the postoperative period.
\*\*\*Administration by Target-Controlled Infusion (TCI)\*\*\*
\*Induction and maintenance of anaesthesia in ventilated patients\*
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic during the induction and maintenance of anaesthesia in ventilated adult patients (see table 1 above for manually controlled infusion). In association with these medicinal products, adequate analgesia for induction of anaesthesia and surgery can generally be achieved with target blood remifentanil concentrations ranging from 3 to 8 nanograms/ml. Remifentanil should be titrated to individual patient response. For particularly stimulating surgical procedures target blood concentrations up to 15 nanograms/ml may be required.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil (see table 1 above for manually controlled infusion)\*.\*
The following table provides the equivalent blood remifentanil concentration using a TCI approach for various manually controlled infusion rates at steady state:
\*Table 2: Remifentanil blood concentrations (nanograms/ml) estimated using the Minto (1997) pharmacokinetic model in a 70 kg, 170 cm, 40 year old male patient for various manually controlled infusion rates (micrograms/kg/min) at steady state\*
| | |
| --- | --- |
| \*\*Remifentanil Infusion Rate\*\* \*\*(micrograms/kg/min)\*\* | \*\*Remifentanil Blood Concentration\*\* \*\*(nanograms/ml)\*\* |
| 0.05 | 1.3 |
| 0.10 | 2.6 |
| 0.25 | 6.3 |
| 0.40 | 10.4 |
| 0.50 | 12.6 |
| 1.0 | 25.2 |
| 2.0 | 50.5 |
As there are insufficient data, the administration of remifentanil by TCI for spontaneous ventilation anaesthesia is not recommended.
\*Guidelines for discontinuation/continuation in the immediate post-operative period\*
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see also \*Guidelines for discontinuation / continuation during immediate postoperative period\* in the section above for \*\*\*Administration by Manually Controlled Infusion (MCI)\*\*\*).
As there are insufficient data, the administration of remifentanil by TCI for the management of post-operative analgesia is not recommended.
\*\*4.2.1.2 Paediatric patients (1 to12 years of age)\*\*
Co-administration of remifentanil and an intravenous anaesthetic agent for induction of anaesthesia has not been studied in detail and is therefore not recommended.
Remifentanil TCI has not been studied in paediatric patients and therefore administration of remifentanil by TCI is not recommended in these patients.
\*Induction of anaesthesia\*
The use of remifentanil for induction of anaesthesia in patients aged 1 to 12 years is not recommended as there are no data available in this patient population.
\*Maintenance of anaesthesia\*
The following doses of remifentanil (see table 3) are recommended for maintenance of anaesthesia:
\*Table 3: Dosing Guideline for Paediatric Patients (1 to 12 years of age)\*
| | | | |
| --- | --- | --- | --- |
| \*\*CONCOMITANT ANAESTHETIC\\*\*\* | \*\*REMIFENTANILBOLUS INJECTION\*\* \*\*(micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*(micrograms/kg/min)\*\* | |
| \*\*Starting Rate\*\* | \*\*Maintenance Rate\*\* |
| Halothane (starting dose 0.3 MAC) | 1 | 0.25 | 0.05 to 1.3 |
| Sevoflurane (starting dose 0.3 MAC) | 1 | 0.25 | 0.05 to 0.9 |
| Isoflurane (starting dose 0.5 MAC) | 1 | 0.25 | 0.06 to 0.9 |
\\*co-administered with nitrous oxide / oxygen in a ratio of 2:1
When given by bolus injection remifentanil should be administered \*\*over not less than 30 seconds\*\*. Surgery should not commence until at least 5 minutes after the start of the remifentanil infusion, if a simultaneous bolus dose has not been given.
For sole administration of nitrous oxide (70 %) with remifentanil, infusion rates for maintenance of anaesthesia should be between 0.4 and 3 micrograms/kg/min. Data gained from adults suggest that 0.4 micrograms/kg/min may be a convenient initial dose although specific studies are lacking.
Paediatric patients should be monitored and the dose titrated to the depth of analgesia appropriate for the surgical procedure.
\*Concomitant medicinal products\*
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic required to maintain anaesthesia. Therefore, isoflurane, halothane and sevoflurane should be administered as recommended above to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil.
No conclusive data are available for dose recommendations for simultaneous use of other hypnotics with remifentanil. The dose and duration of concomitant use of benzodiazepines and related drugs should be limited to the lowest effective dose and treatment as short as possible (see above and sections 4.4 and 4.5).
\*Guidelines for patient management in the immediate post-operative period /\*
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of medicinal product(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient's surgical procedure and the level of post-operative care anticipated (see section 4.4).
\*\*4.2.1.3 Neonates/infants (aged less than 1 year)\*\*
There is limited experience of remifentanil in newborn infants and infants (aged under 1 year old; see section 5.1). The pharmacokinetic profile of remifentanil in newborn infants and infants (aged less than 1 year) is comparable to that seen in adults after correction for body weight differences (see section 5.2). However, because there are insufficient clinical data, the administration of remifentanil is not recommended for this age group.
Use for Total Intravenous anaesthesia (TIVA): There is limited clinical trial experience of remifentanil for TIVA in infants (see section 5.1). However, there are insufficient clinical data to make dose recommendations.
\*\*4.2.1.4 Special patient groups\*\*
For dose recommendations for special patient groups (elderly and obese patients, renally and hepatically impaired patients, patients undergoing neurosurgery and ASA III/IV patients; see section 4.2.4).
\*\*\*\*4.2.2 Cardiac anaesthesia\*\*\*\*
\*Administration by Manually Controlled Infusion (MCI)\*
For dose recommendations in patients undergoing cardiac surgery see table 4 below:
\*Table 4: Dosing Guidelines for Cardiac Anaesthesia:\*
| | | | |
| --- | --- | --- | --- |
| \*\*INDICATION\*\* | \*\*REMIFENTANIL BOLUS INJECTION\*\* \*\*(micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*(micrograms/kg/min)\*\* | |
| \*\*Starting Rate\*\* | \*\*Typical infusion Rates\*\* |
| \*\*Induction of anaesthesia\*\* | Not recommended | 1 | \\_ |
| \*\*Maintenance of anaesthesia in ventilated patients\*\* | | | |
| • Isoflurane (starting dose 0.4 MAC) | 0.5 to 1 | 1 | 0.003 to 4 | |
| • Propofol (starting dose 50 micrograms/kg/min) | 0.5 to 1 | 1 | 0.01 to 4.3 | |
| \*\*Continuation of post-operative analgesia, prior to extubation\*\* | Not recommended | 1 | 0 to 1 | |
\*Induction period of anaesthesia\*
After administration of a hypnotic to achieve loss of consciousness, remifentanil should be administered at an initial infusion rate of 1 microgram/kg/min. The use of bolus injections of remifentanil during induction in cardiac surgical patients is not recommended. Endotracheal intubation should not occur until at least 5 minutes after the start of the infusion.
\*Maintenance period of anaesthesia\*
After endotracheal intubation the infusion rate of remifentanil can be titrated upward in 25% to 100% increments, or downward in 25% to 50% decrements, every 2 to 5 minutes according to patient need. Supplemental slow bolus doses, administered over not less than 30 seconds, may also be given every 2 to 5 minutes as required. High risk cardiac patients, such as those undergoing valve surgery or with poor left ventricular function, should be administered a maximum bolus dose of 0.5 micrograms/kg. These dosing recommendations also apply during hypothermic cardiopulmonary bypass (see section 5.2).
\*Concomitant medicinal products\*
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid excessive depth of anaesthesia.
No data are available for dose recommendations for simultaneous use of other hypnotics with remifentanil (see in section above: \*Administration by Manually Controlled Infusion (MCI), Concomitant medicinal products\*).
\*Guidelines for postoperative patient management\*
\*Continuation of post-operative analgesia with remifentanil prior to extubation\*
It is recommended that the infusion of remifentanil should be maintained at the final intra-operative rate during transfer of patients to the post-operative care area. Upon arrival into this area, the patient's level of analgesia and sedation should be closely monitored and the remifentanil infusion rate adjusted to meet the individual patient's requirements (for further information on management of intensive care patients see section 4.2.3).
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation. Prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established. It is therefore recommended that the choice of medicinal product(s), the dose and the time of administration are planned before weaning the patient from the ventilator.
\*Guidelines for discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, hypertension, shivering and pain have been reported in cardiac patients immediately following discontinuation of remifentanil (see section 4.8). To minimise the risk of these occurring, adequate alternative analgesia must be established (as described above), before the remifentanil infusion is discontinued. The infusion rate should be reduced by 25 % decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics. Haemodynamic changes such as hypertension and tachycardia should be treated with alternative medicinal products as appropriate.
\*\*When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.\*\*
\*\*\*Administration by Target-Controlled Infusion\*\*\*
\*Induction and maintenance of anaesthesia\*
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see \*Table 4\*: \*Dosing Guidelines for Cardiac Anaesthesia in section 4.2.2\*). In association with these agents, adequate analgesia for cardiac surgery is generally achieved at the higher end of the range of target blood remifentanil concentrations used for general surgical procedures. Following titration of remifentanil to individual patient response, blood concentrations as high as 20 nanograms/ml have been used in clinical studies.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil (see \*Table 4\*: \*Dosing Guidelines for Cardiac Anaesthesia above\*).
For information on blood remifentanil concentrations achieved with manually controlled infusion see \*Table 2\*: \*Remifentanil Blood Concentrations (nanograms/ml) estimated using the Minto Model (1997)\* in section 4.2.1.1)\*.\*
\*Guidelines for discontinuation / continuation in the immediate post-operative period\*
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see \*Guidelines for discontinuation\* \*in the immediate post-operative period\* in section 4.2.1.1).
As there are insufficient data, the administration of remifentanil by TCI for the management of post-operative analgesia is not recommended.
\*\*\*\*4.2.3 Use in intensive care\*\*\*\*
\*\*4.2.3.1 Adults\*\*
Remifentanil can be used for the provision of analgesia in mechanically ventilated intensive care patients. If required, additionally sedating medicinal products should be applied.
Remifentanil has been studied in mechanically ventilated intensive care patients in well controlled clinical trials for up to three days. As patients were not studied beyond three days, no evidence of safety and efficacy for longer treatment has been established. Therefore, the use of remifentanil is not recommended for a duration of treatment greater than three days.
Due to the lack of data the administration of remifentanil by TCI is not recommended for ICU patients.
In adults, it is recommended that remifentanil is initiated at an infusion rate of 0.1 micrograms/kg/min (6 micrograms/kg/h) to 0.15 micrograms/kg/min (9 micrograms/kg/h). The infusion rate should be titrated in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) to achieve the desired level of sedation and analgesia. A period of at least 5 minutes should be allowed between dose adjustments. The level of sedation and analgesia should be carefully monitored, regularly reassessed and the remifentanil infusion rate adjusted accordingly. If an infusion rate of 0.2 micrograms/kg/min (12 micrograms/kg/h) is reached and the desired level of sedation is not achieved, it is recommended that dosing with an appropriate sedative is initiated (see below). The dose of sedative should be titrated to obtain the desired level of sedation. Further increases to the remifentanil infusion rate in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) may be made if additional analgesia is required.
The following table summarises the starting infusion rates and typical dose range for provision of analgesia and sedation in individual patients:
\*Table 5: Dosing Guidelines for use of remifentanil within the intensive care setting\*
| | |
| --- | --- |
| \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*micrograms/kg/min (micrograms/kg/h)\*\* | |
| \*\*Starting Rate\*\* | \*\*Range\*\* |
| 0.1 (6) to 0.15 (9) | 0.006 (0.36) to 0.74 (44.4) |
Bolus doses of remifentanil are not recommended in the intensive care setting.
The use of remifentanil will reduce the dose requirement of any concomitant sedative medicinal products. Typical starting doses for sedative medicinal products, if required, are given below:
\*Table 6: Recommended starting dose of sedative medicinal products, if required\*
| | | |
| --- | --- | --- |
| \*\*Sedative medicinal product\*\* | \*\*Bolus\*\* \*\*(mg/kg)\*\* | \*\*Infusion rate (mg/kg/h)\*\* |
| Propofol | Up to 0.5 | 0.5 |
| Midazolam | Up to 0.03 | 0.03 |
To allow separate titration of the respective medicinal products, sedative medicinal products should not be administered as an admixture.
\*Additional analgesia for ventilated patients undergoing painful procedures\*
An increase in the existing remifentanil infusion rate may be required to provide additional analgesic cover for ventilated patients undergoing stimulating and/or painful procedures such as endotracheal suctioning, wound dressing and physiotherapy. It is recommended that a remifentanil infusion rate of at least 0.1 micrograms/kg/min (6 micrograms/kg/h) should be maintained for at least 5 minutes prior to the start of the stimulating procedure. Further dose adjustments may be made every 2 to 5 minutes in increments of 25 %-50 % in anticipation of, or in response to, additional requirement for analgesia. A mean infusion rate of 0.25 micrograms/kg/min (15 micrograms/kg/h), maximum 0.75 micrograms/kg/min (45 micrograms/kg/h), has been administered for provision of additional analgesia during painful and stimulating procedures.
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation regardless of the duration of infusion. After administration of remifentanil the potential for the development of tolerance and hyperalgesia should be considered. Therefore, prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established and to prevent hyperalgesia and concomitant haemodynamic changes. It is therefore recommended that the choice of medicinal product(s), the dose and the time of administration are planned prior to discontinuation of remifentanil. Long acting or intravenous or local analgesics, which can be controlled by the health care staff or the patient, are alternative options for analgesia and should be chosen carefully according to the patient's needs.
Prolonged administration of µ-opioid agonists may induce development of tolerance.
\*\*\*Guidelines for extubation and discontinuation of remifentanil\*\*\*
In order to ensure a smooth emergence from a remifentanil-based regimen it is recommended that the infusion rate of remifentanil is titrated in stages to 0.1 micrograms/kg/min (6 micrograms/kg/h) over a period up to 1 hour prior to extubation.
Following extubation, the infusion rate should be reduced by 25 % decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator, the remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.
Upon discontinuation of remifentanil, the IV cannula should be cleared or removed to prevent subsequent inadvertent administration.
\*\*When other opioid medicinal products are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate analgesia must always be balanced against the potential risk of respiratory depression with these medicinal products.\*\*
\*\*4.2.3.2 Paediatric intensive care patients\*\*
The use of remifentanil in intensive care patients under the age of 18 years is not recommended as there are no data available in this patient population.
\*\*4.2.3.3 Renally impaired intensive care patients\*\*
No adjustments to the doses recommended above are necessary in renally-impaired patients, including those undergoing renal replacement therapy, however the clearance of carboxylic acid metabolite is reduced in patients with impaired renal function (see section 5.2).
\*\*\*\*4.2.4 Special populations\*\*\*\*
\*\*4.2.4.1 Elderly (over 65 years of age)\*\*
\*General anaesthesia\*
Caution should be exercised in the administration of remifentanil in this population.
The initial starting dose of remifentanil administered to patients over 65 should be half the recommended adult dose and then titrated to the individual patient's need as an increased sensitivity to the pharmacodynamic effects of remifentanil has been seen in this patient population. This dose adjustment refers to application during all phases of anaesthesia including induction, maintenance and immediate post-operative analgesia.
Because of the increased sensitivity of elderly patients to remifentanil, when administering remifentanil by TCI in this population the initial target concentration should be 1.5 to 4 nanograms/ml with subsequent titration according to the individual patient's response.
\*Anaesthesia during cardiac surgery\*
Reduction of initial dose is not required (see section 4.2.2).
\*Intensive care\*
Reduction of initial dose is not required (see section 4.2.3 \*\*\*Intensive Care\*\*\* above).
\*\*4.2.4.2 Obese patients\*\*
For manually controlled infusion it is recommended that for obese patients the dose of remifentanil should be reduced and based upon ideal body weight as the clearance and volume of distribution of remifentanil are better correlated with ideal body weight than actual body weight.
With the calculation of lean body mass (LBM) used in the Minto model, LBM is likely to be underestimated in female patients with a body mass index (BMI) greater than 35 kg/m2 and in male patients with BMI greater than 40 kg/m2. To avoid underdosing in these patients, remifentanil TCI should be titrated carefully to individual response.
\*\*4.2.4.3 Renally impaired patients\*\*
On the basis of investigations carried out to date, a dose adjustment in patients with impaired renal function, including intensive care patients, is not necessary; however, these patients exhibit reduced clearance of carboxylic acid metabolite.
\*\*4.2.4.4 Patients with hepatic impairment\*\*
No adjustment of the initial dose, relative to that used in healthy adults, is necessary as the pharmacokinetic profile of remifentanil is unchanged in this patient population. However, patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil (see section 4.4). These patients should be closely monitored and the dose of remifentanil titrated to individual patient need.
\*\*4.2.4.5 Neurosurgery patients\*\*
Limited clinical experience in patients undergoing neurosurgery has shown that no special dose recommendations are required.
\*\*4.2.4.6 ASA III/IV patients\*\*
\*General anaesthesia\*
As the haemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of remifentanil in this population. Initial dose reduction and subsequent titration to effect is therefore recommended.
Data material is not conclusive for the application of remifentanil in paediatric ASA III/IV patients and therefore dose recommendations are not given.
For TCI, a lower initial target of 1.5 to 4 nanograms/ml should be used in ASA III or IV patients and subsequently titrated to response.
\*Cardiac anaesthesia\*
No initial dose reduction is required (see section 4.2.2).
\*\*\*\*4.2.5 Guidelines for remifentanil infusion rates for manually controlled infusion (MCI)\*\*\*\*
\*\*\*Table 7: Remifentanil infusion rates (ml/kg/h)\*\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Drug Delivery Rate\*\* | \*\*Infusion Rate (ml/kg/h) for solutions with concentrations of\*\* | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*20 micrograms/ml\*\* | \*\*25 micrograms/ml\*\* | \*\*50 micrograms/ml\*\* | \*\*250 micrograms/ml\*\* |
| \*\*1mg/50ml\*\* | \*\*1mg/40ml\*\* | \*\*1mg/20ml\*\* | \*\*10mg/40ml\*\* |
| \*\*0.0125\*\* | 0.038 | 0.03 | 0.015 | Not recommended |
| \*\*0.025\*\* | 0.075 | 0.06 | 0.03 | Not recommended |
| \*\*0.05\*\* | 0.15 | 0.12 | 0.06 | 0.012 |
| \*\*0.075\*\* | 0.23 | 0.18 | 0.09 | 0.018 |
| \*\*0.1\*\* | 0.3 | 0.24 | 0.12 | 0.024 |
| \*\*0.15\*\* | 0.45 | 0.36 | 0.18 | 0.036 |
| \*\*0.2\*\* | 0.6 | 0.48 | 0.24 | 0.048 |
| \*\*0.25\*\* | 0.75 | 0.6 | 0.3 | 0.06 |
| \*\*0.5\*\* | 1.5 | 1.2 | 0.6 | 0.12 |
| \*\*0.75\*\* | 2.25 | 1.8 | 0.9 | 0.18 |
| \*\*1.0\*\* | 3.0 | 2.4 | 1.2 | 0.24 |
| \*\*1.25\*\* | 3.75 | 3.0 | 1.5 | 0.3 |
| \*\*1.5\*\* | 4.5 | 3.6 | 1.8 | 0.36 |
| \*\*1.75\*\* | 5.25 | 4.2 | 2.1 | 0.42 |
| \*\*2.0\*\* | 6.0 | 4.8 | 2.4 | 0.48 |
\*\*\*Table 8: Remifentanil infusion rates (ml/h) for a 20 micrograms/ml solution\*\*\*
| | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*5\*\* | \*\*10\*\* | \*\*20\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* |
| \*\*0.0125\*\* | 0.188 | 0.375 | 0.75 | 1.125 | 1.5 | 1.875 | 2.25 |
| \*\*0.025\*\* | 0.375 | 0.75 | 1.5 | 2.25 | 3.0 | 3.75 | 4.5 |
| \*\*0.05\*\* | 0.75 | 1.5 | 3.0 | 4.5 | 6.0 | 7.5 | 9.0 |
| \*\*0.075\*\* | 1.125 | 2.25 | 4.5 | 6.75 | 9.0 | 11.25 | 13.5 |
| \*\*0.1\*\* | 1.5 | 3.0 | 6.0 | 9.0 | 12.0 | 15.0 | 18.0 |
| \*\*0.15\*\* | 2.25 | 4.5 | 9.0 | 13.5 | 18.0 | 22.5 | 27.0 |
| \*\*0.2\*\* | 3.0 | 6.0 | 12.0 | 18.0 | 24.0 | 30.0 | 36.0 |
| \*\*0.25\*\* | 3.75 | 7.5 | 15.0 | 22.5 | 30.0 | 37.5 | 45.0 |
| \*\*0.3\*\* | 4.5 | 9.0 | 18.0 | 27.0 | 36.0 | 45.0 | 54.0 |
| \*\*0.35\*\* | 5.25 | 10.5 | 21.0 | 31.5 | 42.0 | 52.5 | 63.0 |
| \*\*0.4\*\* | 6.0 | 12.0 | 24.0 | 36.0 | 48.0 | 60.0 | 72.0 |
\*\*\*Table 9: Remifentanil infusion rates (ml/h) for a 25 micrograms/ml solution\*\*\*
| | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*10\*\* | \*\*20\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.0125\*\* | 0.3 | 0.6 | 0.9 | 1.2 | 1.5 | 1.8 | 2.1 | 2.4 | 2.7 | 3.0 |
| \*\*0.025\*\* | 0.6 | 1.2 | 1.8 | 2.4 | 3.0 | 3.6 | 4.2 | 4.8 | 5.4 | 6.0 |
| \*\*0.05\*\* | 1.2 | 2.4 | 3.6 | 4.8 | 6.0 | 7.2 | 8.4 | 9.6 | 10.8 | 12.0 |
| \*\*0.075\*\* | 1.8 | 3.6 | 5.4 | 7.2 | 9.0 | 10.8 | 12.6 | 14.4 | 16.2 | 18.0 |
| \*\*0.1\*\* | 2.4 | 4.8 | 7.2 | 9.6 | 12.0 | 14.4 | 16.8 | 19.2 | 21.6 | 24.0 |
| \*\*0.15\*\* | 3.6 | 7.2 | 10.8 | 14.4 | 18.0 | 21.6 | 25.2 | 28.8 | 32.4 | 36.0 |
| \*\*0.2\*\* | 4.8 | 9.6 | 14.4 | 19.2 | 24.0 | 28.8 | 33.6 | 38.4 | 43.2 | 48.0 |
\*\*\*Table 10: Remifentanil infusion rates (ml/h) for a 50 micrograms/ml solution\*\*\*
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.025\*\* | 0.9 | 1.2 | 1.5 | 1.8 | 2.1 | 2.4 | 2.7 | 3.0 |
| \*\*0.05\*\* | 1.8 | 2.4 | 3.0 | 3.6 | 4.2 | 4.8 | 5.4 | 6.0 |
| \*\*0.075\*\* | 2.7 | 3.6 | 4.5 | 5.4 | 6.3 | 7.2 | 8.1 | 9.0 |
| \*\*0.1\*\* | 3.6 | 4.8 | 6.0 | 7.2 | 8.4 | 9.6 | 10.8 | 12.0 |
| \*\*0.15\*\* | 5.4 | 7.2 | 9.0 | 10.8 | 12.6 | 14.4 | 16.2 | 18.0 |
| \*\*0.2\*\* | 7.2 | 9.6 | 12.0 | 14.4 | 16.8 | 19.2 | 21.6 | 24.0 |
| \*\*0.25\*\* | 9.0 | 12.0 | 15.0 | 18.0 | 21.0 | 24.0 | 27.0 | 30.0 |
| \*\*0.5\*\* | 18.0 | 24.0 | 30.0 | 36.0 | 42.0 | 48.0 | 54.0 | 60.0 |
| \*\*0.75\*\* | 27.0 | 36.0 | 45.0 | 54.0 | 63.0 | 72.0 | 81.0 | 90.0 |
| \*\*1.0\*\* | 36.0 | 48.0 | 60.0 | 72.0 | 84.0 | 96.0 | 108.0 | 120.0 |
| \*\*1.25\*\* | 45.0 | 60.0 | 75.0 | 90.0 | 105.0 | 120.0 | 135.0 | 150.0 |
| \*\*1.5\*\* | 54.0 | 72.0 | 90.0 | 108.0 | 126.0 | 144.0 | 162.0 | 180.0 |
| \*\*1.75\*\* | 63.0 | 84.0 | 105.0 | 126.0 | 147.0 | 168.0 | 189.0 | 210.0 |
| \*\*2.0\*\* | 72.0 | 96.0 | 120.0 | 144.0 | 168.0 | 192.0 | 216.0 | 240.0 |
\*\*\*Table 11: Remifentanil infusion rates (ml/h) for a 250 micrograms/ml solution\*\*\*
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.1\*\* | 0.72 | 0.96 | 1.20 | 1.44 | 1.68 | 1.92 | 2.16 | 2.40 |
| \*\*0.15\*\* | 1.08 | 1.44 | 1.80 | 2.16 | 2.52 | 2.88 | 3.24 | 3.60 |
| \*\*0.2\*\* | 1.44 | 1.92 | 2.40 | 2.88 | 3.36 | 3.84 | 4.32 | 4.80 |
| \*\*0.25\*\* | 1.80 | 2.40 | 3.00 | 3.60 | 4.20 | 4.80 | 5.40 | 6.00 |
| \*\*0.5\*\* | 3.60 | 4.80 | 6.00 | 7.20 | 8.40 | 9.60 | 10.80 | 12.00 |
| \*\*0.75\*\* | 5.40 | 7.20 | 9.00 | 10.80 | 12.60 | 14.40 | 16.20 | 18.00 |
| \*\*1.0\*\* | 7.20 | 9.60 | 12.00 | 14.40 | 16.80 | 19.20 | 21.60 | 24.00 |
| \*\*1.25\*\* | 9.00 | 12.00 | 15.00 | 18.00 | 21.00 | 24.00 | 27.00 | 30.00 |
| \*\*1.5\*\* | 10.80 | 14.40 | 18.00 | 21.60 | 25.20 | 28.80 | 32.40 | 36.00 |
| \*\*1.75\*\* | 12.60 | 16.80 | 21.00 | 25.20 | 29.40 | 33.60 | 37.80 | 42.00 |
| \*\*2.0\*\* | 14.40 | 19.20 | 24.00 | 28.80 | 33.60 | 38.40 | 43.20 | 48.00 |
\*\*Method of administration\*\*
Remifentanil is intended for intravenous use only and must not be administered as an epidural or intrathecal injection (see section 4.3).
Continuous infusions of remifentanil must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space (see section 4.2.5 for tables with examples of infusion rates by body weight to help titrate remifentanil to the patient`s anaesthetic needs).
Care should be taken to avoid obstruction or disconnection of infusion lines and to adequately clear the lines to remove residual remifentanil after use (see section 4.4). IV lines/infusion systems should be removed after cessation of use to avoid inadvertent administration.
Remifentanil may also be given by target-controlled infusion (TCI) with an approved infusion device incorporating the Minto pharmacokinetic model with covariates for age and lean body mass (LBM).
After reconstitution of the lyophilized powder, remifentanil must not be administered without further dilution.
For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.4.3 Contraindications
Hypersensitivity to the active substance, to other fentanyl analogues or to any of the excipients listed in section 6.1.
Remifentanil is contra-indicated for use as the sole medicinal product for induction of anaesthesia.
As glycine is present in the formulation, Remifentanil is contraindicated for epidural and intrathecal use (see section 5.3).4.4 Special warnings and precautions for use
Remifentanil should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic medicinal products and the recognition and management of the expected undesirable effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.
The use of remifentanil in mechanically ventilated intensive care patients is not recommended for a duration of treatment greater than 3 days.
Patients with a known hypersensitivity to opioids of a different class may exhibit a hypersensitivity reaction following administration of remifentanil. Caution should be exercised before using remifentanil in these patients.
Remifentanil should not be used as an analgesic in procedures where patients remain conscious or do not receive any airway support during the procedure.
\*\*Rapid offset of action/transition to alternative analgesia\*\*
Due to the very rapid offset of action of remifentanil, patients may emerge rapidly from anaesthesia and no residual opioid activity will be present within 5-10 minutes after the discontinuation of remifentanil. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. During administration of remifentanil as a μ-opioid agonist the potential for the development of tolerance, hyperalgesia and associated haemodynamic changes should be considered. Therefore, prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established and to prevent hyperalgesia and concomitant haemodynamic changes.
For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of post-operative care.
When other opioid medicinal products are administered as part of the regimen for transition to alternative analgesia, the benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these medicinal products.
\*\*Risk from concomitant use of sedative medicinal products such as benzodiazepines or related medicinal products\*\*
Concomitant use of Remifentanil and sedative medicinal products such as benzodiazepines or related medicinal products may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Remifentanil concomitantly with sedative medicinal products, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
\*\*Tolerance and opioid use disorder (abuse and dependence)\*\*
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids. Abuse or intentional misuse of opioids may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
\*\*Discontinuation of treatment and withdrawal syndrome\*\*
Repeated administration at short term intervals for prolonged periods may result in the development of withdrawal syndrome after cessation of therapy. Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days. Where reported, re-introduction and tapering of the infusion has been beneficial. The use of remifentanil in mechanically ventilated intensive care patients is not recommended for duration of treatment greater than 3 days.
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with remifentanil.
To minimise symptoms of withdrawal tapering from a high dose may take weeks to months.
Additional to the symptoms mentioned above the opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, or increased respiratory rate.
\*\*Muscle rigidity - prevention and management\*\*
At the doses recommended muscle rigidity may occur. The incidence of muscle rigidity is related to the dose and rate of administration. Therefore, bolus injections should be administered over not less than 30 seconds.
Muscle rigidity induced by remifentanil must be treated in the context of the patient's clinical condition with appropriate supporting measures including ventilatory support. Excessive muscle rigidity occurring during the induction of anaesthesia should be treated by the administration of a neuromuscular blocking medicinal product and/or additional hypnotics. Muscle rigidity seen during the use of remifentanil as an analgesic may be treated by stopping or decreasing the rate of administration of remifentanil. Resolution of muscle rigidity after discontinuing the infusion of remifentanil occurs within minutes. Alternatively, a µ-opioid antagonist may be administered; however, this may reverse or attenuate the analgesic effect of remifentanil.
\*\*Hyperalgesia\*\*
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
\*\*Respiratory depression – preventive measures and treatment\*\*
Profound analgesia is accompanied by marked respiratory depression. Therefore, remifentanil should only be used in areas where facilities for monitoring and dealing with respiratory depression are available. Special care should be taken in patients with impaired lung function and with severe hepatic impairment. These patients may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil titrated to individual patient need.
The appearance of respiratory depression should be managed appropriately, including decreasing the rate of infusion by 50 %, or by a temporary discontinuation of the infusion. Remifentanil has not been shown to cause recurrent respiratory depression even after prolonged administration. However, in the presence of confounding factors (e.g. inadvertent administration of bolus doses (see section below) and administration of concomitant longer acting opioids), respiratory depression occurring up to 50 minutes after discontinuation of infusion has been reported. As many factors may affect post-operative recovery, it is important to ensure that full consciousness and adequate spontaneous ventilation are achieved before the patient is discharged from the recovery area.
\*\*Cardiovascular effects\*\*
Hypotension and bradycardia can give rise to asystole and cardiac arrest (see sections 4.5 and 4.8) may be managed by reducing the rate of infusion of remifentanil or the dose of concurrent anaesthetics or by using IV fluids, vasopressor or anticholinergic medicinal products as appropriate.
Debilitated, hypovolaemic, and elderly patients may be more sensitive to the cardiovascular effects of remifentanil.
\*\*Inadvertent administration\*\*
A sufficient amount of remifentanil may be present in the dead space of the IV line and/or cannula to cause respiratory depression, apnoea and/or muscle rigidity if the line is flushed with IV fluids or other medicinal products. This may be avoided by administering remifentanil into a fast flowing IV line or via a dedicated IV line which is removed when remifentanil is discontinued.
\*\*Neonates/infants\*\*
There is limited data available on use in newborn infants and infants under 1 year of age (see sections 4.2. and 5.1).4.5 Interaction with other medicinal products and other forms of interaction
Remifentanil is not metabolised by plasmacholinesterase, therefore, interactions with medicinal products metabolised by this enzyme are not anticipated.
Remifentanil, whether given by manually controlled infusion or TCI, decreases the amounts or doses of inhalational and IV anaesthetics, and benzodiazepines required for anaesthesia (see below and sections 4.2 and 4.4). If doses of concomitantly administered CNS depressant medicinal products are not reduced patients may experience an increased incidence of adverse effects associated with these medicinal products.
The cardiovascular effects of remifentanil (hypotension and bradycardia), may exacerbate in patients receiving concomitant cardiac depressant medicinal products, such as beta-blockers and calcium channel blocking medicinal products (see also sections 4.4 and 4.8).
If concomitant use of other serotonergic medicinal products is warranted, patients should be monitored for serotonin syndrome, particularly during initiation of therapy and dose increases. If serotonin syndrome is suspected, treatment with remifentanil, other opiate therapy, and/or any concurrently administered serotonergic medicinal products should be discontinued.
Sedative medicinal products such as benzodiazepines or related medicinal products:
The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.
Co-administration of remifentanil with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) or Monoamine Oxidase Inhibitors (MAOIs) may increase the risk of serotonin syndrome, a potentially life-threatening condition. Caution should be exercised with concomitant use of MAOIs. Irreversible MAOIs should be discontinued at least 2 weeks prior to remifentanil use.
After receiving remifentanil, it is advisable that alcoholic drink is avoided.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are no adequate and well-controlled studies in pregnant women.
Animal studies have shown reproductive toxicity (see section 5.3).
Remifentanil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
\*\*Labour and delivery\*\*
The safety profile of remifentanil during labour and delivery has not been researched. There are insufficient data to recommend remifentanil for use during labour and caesarean section. Remifentanil crosses the placental barrier, and fentanyl analogues can cause respiratory depression in the child. In case remifentanil is administered nevertheless, the patient and the neonate must be monitored for signs of excess sedation or respiratory depression (see section 4.4).
\*\*Breast-feeding\*\*
It is not known whether remifentanil is excreted in human breast milk. However, because fentanyl analogues are excreted in breast milk and remifentanil-related material was found in rat milk after dosing with remifentanil, breast-feeding mothers should be advised to discontinue breast-feeding for 24 hours following administration of remifentanil.
For a summary of the reproductive toxicity study findings please refer to Section 5.3 Preclinical safety data.4.7 Effects on ability to drive and use machines
Remifentanil has major influence on the ability to drive and use machines.
If an early discharge is envisaged after application of remifentanil, following treatment using anaesthetic medicinal products, patients should be advised not to drive or operate machinery. It is advisable that the patient is accompanied when returning home and that alcoholic drink is avoided.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely4.8 Undesirable effects
The most common undesirable effects associated with remifentanil are direct consequences of the effects of μ-opioid agonists. These undesirable effects resolve within minutes of discontinuing or decreasing the rate of remifentanil administration.
The following frequencies have been used in order to classify the occurrence of undesirable effects:
| | |
| --- | --- |
| Very common | ≥ 1/10 |
| Common | ≥ 1/100 to < 1/10 |
| Uncommon | ≥ 1/1,000 to < 1/100 |
| Rare | ≥ 1/10,000 to < 1/1,000 |
| Very rare | < 1/10,000 |
| not known (cannot be estimated from the available data) | |
Incidence is listed below within each system organ class:
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reactions\*\* |
| Immune system disorders | Rare | allergic reactions including anaphylaxis have been reported in patients receiving remifentanil in conjunction with one or more anaesthetic agents |
| Not known | anaphylactic shock |
| Psychiatric disorders | Not known | drug dependence (see section 4.4), withdrawal syndrome |
| Nervous system disorders | Very common | skeletal muscle rigidity |
| Rare | sedation (during awakening after general anaesthesia) |
| Not known | convulsions |
| Cardiac disorders | Common | bradycardia |
| Rare | asystole/cardiac arrest with preceding bradycardia in patients treated with remifentanil in combination with other anaesthetics |
| Not known | atrioventricular block, arrhythmia |
| Vascular disorders | Very common | hypotension |
| Common | post-operatively occurring hypertension |
| Respiratory, thoracic and mediastinal disorders | Common | acute respiratory depression, apnoea, cough |
| Uncommon | hypoxia |
| Gastrointestinal disorders | Very common | nausea, vomiting |
| Uncommon | constipation |
| Skin and subcutaneous tissue disorders | Common | pruritus |
| General disorders and administration site conditions | Common | post-operative shivering |
| Uncommon | post-operative pain |
| Not known | drug tolerance |
\*\*Discontinuation of treatment\*\*
Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported rarely upon abrupt cessation, particularly after prolonged administration of more than 3 days (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Overdose would be manifested by an extension of the pharmacologically predictable actions of remifentanil. Due to the very short duration of action of remifentanil, the potential for deleterious effects due to overdose is limited to the immediate time period following administration of the medicinal product. Response to discontinuation of the medicinal product is rapid, with return to baseline within ten minutes.
\*\*Management\*\*
In the event of overdose, or suspected overdose, the following actions should be taken: discontinue administration of remifentanil, a patent airway should be maintained, assisted or controlled ventilation with oxygen initiated, and adequate cardiovascular function maintained. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking medicinal product may be required to facilitate assisted or controlled respiration. Intravenous fluids and vasopressor medicinal products may be administered for the treatment of hypotension. Other supportive measures may be useful.
Intravenous administration of an opioid antagonist such as naloxone may be indicated as a specific antidote in addition to ventilatory support to manage severe respiratory depression. The duration of respiratory depression following overdose with remifentanil is unlikely to exceed the duration of action of the opioid antagonist.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: anaesthetics, general; opioid anaesthetics
ATC-Code: N01AH06
Remifentanil is a selective μ-opioid agonist with a rapid onset and very short duration of action. The μ-opioid activity, of remifentanil, is antagonised by narcotic antagonists, such as naloxone.
Assays of histamine in patients and healthy volunteers have shown no elevation in histamine levels after administration of remifentanil in bolus doses up to 30 micrograms/kg.
\*\*Neonates/infants (aged less than 1 year)\*\*
In a randomised (ratio of 2:1, remifentanil:halothane), open label, parallel group, multicentre study in 60 young infants and newborn infants ≤8 weeks of age (mean 5.5 weeks) with an ASA physical status of I-II who were undergoing pyloromyotomy, the efficacy and safety of remifentanil (given as a 0.4 micrograms/kg/min initial continuous infusion plus supplemental doses or infusion rate changes as needed) was compared with halothane (given at 0.4% with supplemental increases as needed). Maintenance of anaesthesia was achieved by the additional administration of 70 % nitrous oxide (N2O) plus 30 % oxygen. Recovery times were superior in the remifentanil relative to the halothane groups (not significant).
\*\*Use for Total Intravenous anaesthesia (TIVA) - children aged 6 months to 16 years\*\*
TIVA with remifentanil in paediatric surgery was compared to inhalation anaesthesia in three randomised, open-label studies. The results are summarised in the table below.
| | | | |
| --- | --- | --- | --- |
| \*\*Surgical intervention\*\* | \*\*Age (y), (N)\*\* | \*\*Study condition (maintenance)\*\* | \*\*Extubation (min)\*\* \*\*(mean (SD))\*\* |
| Lower abdominal/urological surgery | 0.5-16 (120) | TIVA: propofol (5-10 mg/kg/h) + remifentanil (0.125-1.0 micrograms/kg/min) Inhalational anaesthesia: sevoflurane (1.0-1.5 MAC) + remifentanil (0.125-1.0 micrograms/kg/min) | 11.8 (4.2) 15.0 (5.6) (p<0.05) |
| ENT-surgery | 4-11 (50) | TIVA: propofol (3 mg/kg/h) + remifentanil (0.5 micrograms/kg/min) Inhalational anaesthesia: desflurane (1.3 MAC) + N2O mixture | 11 (3.7) 9.4 (2.9) not significant |
| General or ENT surgery | 2-12 (153) | TIVA: propofol (100-200 micrograms/kg/min) + remifentanil (0.2-0.5 micrograms/kg/min) Inhalational anaesthesia: sevoflurane (1.0-1.5 MAC) + N2O mixture | comparable extubation times (based on limited data) |
In the study in lower abdominal/urological surgery comparing remifentanil/propofol with remifentanil/sevoflurane, hypotension occurred significantly more often under remifentanil/sevoflurane, and bradycardia occurred significantly more often under remifentanil/propofol. In the study in ENT surgery comparing remifentanil/propofol with desflurane/nitrous oxide, a significantly higher heart rate was seen in subjects receiving desflurane/nitrous oxide compared with remifentanil/propofol and with baseline values.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Blood concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. For every 0.1 micrograms/kg/min increase in i.v. infusion rate, the blood concentration of remifentanil will rise by 2.5 nanograms/ml.
\*\*Distribution\*\*
Remifentanil is approximately 70 % bound to plasma proteins.
The central volume of distribution is 100 ml/kg and the steady-state volume of distribution is 350 ml/kg.
\*\*Placental and breast milk transfer\*\*
In a human clinical trial, the average maternal remifentanil concentrations were approximately twice those seen in the foetus. In some cases, however, foetal concentrations were similar to those in the mother. The umbilical arteriovenous ratio of remifentanil concentrations was approximately 30 % suggesting metabolism of remifentanil in the neonate. Remifentanil related material is transferred to the milk of lactating rats.
\*\*Biotransformation\*\*
Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of an essentially inactive carboxylic acid metabolite (1/4600th as potent as remifentanil). Studies in man indicate that all pharmacological activity is associated with the parent compound. The activity of this metabolite is therefore not of any clinical relevance.
The half-life of the metabolite in healthy adults is 2 hours. Approximately 95 % of remifentanil as the carboxylic acid metabolite is recovered in the urine in patients with normal renal function.
Remifentanil is not a substrate for plasma cholinesterase.
\*\*Elimination\*\*
Following administration of the recommended doses of remifentanil, the effective biological half-life is 3-10 minutes.
The average clearance of remifentanil in young healthy adults is 40 ml/min/kg.
\*\*Special patient groups\*\*
\*\*Elderly patients\*\*
The clearance of remifentanil is slightly reduced (by approximately 25 %) in elderly patients (over 65 years of age) compared to that in young patients. The pharmacodynamic activity of remifentanil increases with increasing age. Elderly patients have a remifentanil EC50 for formation of delta waves on the electroencephalogram that is 50 % lower than young patients; therefore, the initial dose of remifentanil should be reduced by 50 % in elderly patients and then carefully titrated to meet the individual patient need.
\*\*Paediatric patients\*\*
The average clearance and steady state volume of distribution of remifentanil are increased in younger children and decline to young healthy adult values by age 17. The elimination half-life of remifentanil in newborn infants is not significantly different from that of young healthy adults. Changes in analgesic effect after changes in infusion rate of remifentanil should be rapid and similar to those seen in young healthy adults. The pharmacokinetics of the carboxylic acid metabolite in paediatric patients between 2 and 17 years of age are similar to those seen in adults after correcting for differences in body weight.
\*\*Cardiac anaesthesia\*\*
The clearance of remifentanil is reduced by approximately 20 % during hypothermic (28°C) cardiopulmonary bypass. A decrease in body temperature lowers elimination clearance by 3 % per degree centigrade.
\*\*Renal impairment\*\*
The rapid recovery from remifentanil-based sedation and analgesia is unaffected by renal status.
The pharmacokinetics of remifentanil are not significantly changed in patients with varying degrees of renal impairment even after administration for up to 3 days in the intensive care setting.
The clearance of the carboxylic acid metabolite is reduced in patients with renal impairment. In intensive care patients with moderate/severe renal impairment, the concentration of the carboxylic acid metabolite is expected to reach approximately 250-fold the level of remifentanil at steady-state. Clinical data demonstrate that the accumulation of the metabolite does not result in clinically relevant μ-opioid effects even after administration of remifentanil infusions for up to 3 days in these patients.
Up to now, data on safety and pharmacokinetic activity of metabolites after infusion of remifentanil for more than 3 days are lacking.
There is no evidence that remifentanil is extracted during renal replacement therapy.
25-30% of the carboxylic acid metabolite is extracted during haemodialysis. In patients with anuria the half-life of the carboxylic acid metabolite is increased to 30 hours.
\*\*Hepatic impairment\*\*
The pharmacokinetics of remifentanil are not changed in patients with severe hepatic impairment awaiting liver transplant, or during the anhepatic phase of liver transplant surgery. Patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil should be titrated to the individual patient need.5.3 Preclinical safety data
Remifentanil, like some other fentanyl analogues, produced increases in action potential duration (APD) in dog isolated Purkinje fibres. After administration of remifentanil, effects were observed at concentrations of 1 micromolar and above (which are higher than plasma concentrations occurring in clinical practice). There were no effects at a remifentanil concentration of 0.1 micromolar. The main metabolite remifentanil acid showed no effect on the APD up to the maximum tested concentration of 10 micromolar.
\*\*Acute toxicity\*\*
Expected signs of μ-opioid intoxication were observed in non-ventilated mice, rats, and dogs after large single bolus intravenous doses of remifentanil. In these studies, the most sensitive species, the male rat, survived following administration of 5 mg/kg.
Intracranial bleedings in dogs caused by hypoxia declined within 14 days after stopping remifentanil application.
\*\*Chronic toxicity\*\*
Bolus doses of remifentanil administered to non-ventilated rats and dogs resulted in respiratory depression in all dose groups, and in reversible intracranial bleedings in dogs. Subsequent investigations showed that the microhaemorrhages resulted from hypoxia and were not specific to remifentanil. Brain microhaemorrhages were not observed in infusion studies in non-ventilated rats and dogs because these studies were conducted at doses that did not cause severe respiratory depression.
It can be inferred from preclinical studies that respiratory depression and associated sequelae are the most likely cause of potentially serious adverse events in humans.
Intrathecal administration to dogs of the glycine formulation alone (i.e. without remifentanil) evoked agitation, pain and hind limb dysfunction and incoordination. These effects are believed to be secondary to the glycine excipient. Because of the better buffering properties of blood, the more rapid dilution, and the low glycine concentration of the Remifentanil formulation, this finding has no clinical relevance for intravenous administration of Remifentanil.
\*\*Reproductive toxicity studies\*\*
Placental transfer studies in rats and rabbits showed that pups are exposed to remifentanil and/or its metabolites during growth and development. Remifentanil-related material is transferred to the milk of lactating rats.
Remifentanil has been shown to reduce fertility in male rats when tested after at least 70 days of daily IV administration of 0.5 mg/kg, which is approximately 0.2 times a human intravenous infusion of an induction dose of 1 microgram/kg with a maintenance dose of 2 micrograms/kg in terms of mg/m2 of body surface area for a surgical procedure lasting 3 hours \*\*or\*\* 40 times a single bolus human dose of 2 micrograms/kg, in terms of mg/m2 of body surface area.
The fertility of female rats was not affected at IV doses up to 1 mg/kg which is 0.4 times a human intravenous infusion of an induction dose of 1 microgram/kg with a maintenance dose of 2 micrograms/kg/min in terms of mg/m2 of body surface area for a surgical procedure lasting 3 hours or approximately 80 times a single bolus human dose of 2 micrograms/kg, in terms of mg/m2 of body surface area, when administered for at least 15 days prior to mating.
No teratogenic effects have been observed with remifentanil at doses up to 5 mg/kg in rats and 0.8 mg/kg in rabbits. Administration of remifentanil to rats throughout late gestation and lactation at doses up to 5 mg/kg IV had no significant effect on the survival, development, or reproductive performance of the F1 generation.
\*\*Genotoxicity\*\*
Remifentanil did not yield positive findings in a series of \*in vitro\* and \*in vivo\* genotoxicity tests, except in the \*in vitro\* mouse lymphoma tk assay, which gave a positive result with metabolic activation. Since the mouse lymphoma results could not be confirmed in further \*in vitro\* and \*in vivo\* tests, treatment with remifentanil is not considered to pose a genotoxic hazard to patients.
\*\*Carcinogenicity\*\*
Long term animal carcinogenicity studies have not been performed with remifentanil.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Glycine
Hydrochloric acid (for pH-adjustment)6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Remifentanil should not be admixed with Lactated Ringer's Injection or Lactated Ringer's and glucose 50 mg/ml (5 %) solution for injection.
Remifentanil should not be mixed with propofol in the same intravenous admixture solution. For compatibility when given into a running i.v. catheter, please see section 6.6.
Administration of Remifentanil into the same intravenous line with blood/serum/plasma is not recommended as non-specific esterase in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.
Remifentanil should not be mixed with other therapeutic medicinal products prior to administration.6.3 Shelf life
2 years
\*After reconstitution/dilution:\*
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
Do not store above 25°C.
For storage conditions after reconstitution/dilution of the medicinal product, see section 6.3.6.5 Nature and contents of container
10 ml vial of colourless type I glass with bromobutyl rubber stopper and cap
Pack size: 5 vials per pack
Not all pack sizes may be marketed6.6 Special precautions for disposal and other handling
\*\*Reconstitution:\*\*
Remifentanil should be prepared for intravenous use by adding the appropriate volume (as stated in the table below) of one of the below listed diluents to give a reconstituted solution with a concentration of approximately 1mg/ml.
| | | |
| --- | --- | --- |
| \*\*Presentation\*\* | \*\*Volume of diluent to be added\*\* | \*\*Concentration of the reconstituted solution\*\* |
| Remifentanil 1 mg | 1 ml | 1 mg/ml |
| Remifentanil 2 mg | 2 ml | 1 mg/ml |
| Remifentanil 5 mg | 5 ml | 1 mg/ml |
Shake until completely dissolved. The reconstituted solution should be clear, colourless and free of visible particles.
\*\*Further Dilution:\*\*
After reconstitution, Remifentanil must not be used without further dilution to concentrations of 20 to 250 micrograms/ml with one of the injection solutions listed below (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).
For target-controlled infusion (TCI) the recommended dilution of Remifentanil is 20 to 50 micrograms/ml.
The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.
One of the following solutions should be used for dilution:
• Water for Injections
• Glucose 50 mg/ml (5 %) solution for injection
• Glucose 50 mg/ml (5 %) solution for injection and sodium chloride 9 mg/ml (0.9 %) solution for injection
• Sodium chloride 9 mg/ml (0.9 %) solution for injection
• Sodium chloride 4.5 mg/ml (0.45 %) solution for injection
The following intravenous fluids may also be used when administered into a running IV catheter:
• Lactated Ringer's Injection
• Lactated Ringer's and glucose 50 mg/ml (5 %) solution for injection
Remifentanil is compatible with propofol when administered into a running IV catheter.
No other diluents should be used.
The solution is to be inspected visually for particulate matter prior to administration. The solution should only be used if the solution is clear and free from particles.
Ideally, intravenous infusions of Remifentanil should be prepared at the time of administration (see section 6.3).
The content of the vial is for single use only.
Any unused product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
One vial contains 5 mg remifentanil (as remifentanil hydrochloride).
Each 1 ml of solution for injection/infusion contains 5 mg remifentanil when reconstituted as directed.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Powder for concentrate for solution for injection/infusion
White to off-white or yellowish, compact powder
## Clinical Particulars
4.1 Therapeutic indications
Remifentanil is indicated as an analgesic for use during induction and/or maintenance of general anaesthesia under close supervision.
Remifentanil is indicated for provision of analgesia in mechanically ventilated intensive care patients 18 years of age and over.4.2 Posology and method of administration
\*\*Remifentanil should only be administered in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the use of anaesthetics and the recognition and management of the expected adverse effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.\*\*
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with remifentanil in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
\*\*Posology\*\*
\*\*\*\*4.2.1 General Anaesthesia\*\*\*\*
The administration of remifentanil must be individualised based on the patient's response.
\*\*4.2.1.1 Adults\*\*
\*\*\*Administration by Manually Controlled Infusion (MCI)\*\*\*
\*Table 1: Dosing Guidelines for Adults\*
| | | | |
| --- | --- | --- | --- |
| | \*\*REMIFENTANIL BOLUS INJECTION (micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION (micrograms/kg/min)\*\* | |
| \*\*Starting\*\* \*\*Rate\*\* | \*\*Range\*\* | |
| \*\*Induction of anaesthesia\*\* | | | |
| 1 (given over not less than 30 sec.) | 0.5 to 1 | - | |
| \*\*Concomitant anaesthetic\*\* | \*\*Maintenance of anaesthesia in ventilated patients\*\* | | | |
| • Nitrous oxide (66 %) | 0.5 to 1 | 0.4 | 0.1 to 2 | |
| • Isoflurane (starting dose 0.5 MAC) | 0.5 to 1 | 0.25 | 0.05 to 2 | |
| • Propofol (Starting dose 100 micrograms/kg/min) | 0.5 to 1 | 0.25 | 0.05 to 2 | |
When given by bolus injection at induction remifentanil should be administered over not less than 30 seconds.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic medicinal products required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects of remifentanil (hypotension and bradycardia).
No data are available for dose recommendations for simultaneous use of other hypnotics other than those listed in the table with remifentanil.
\*Induction of anaesthesia\*
Remifentanil should be administered with a standard dose of hypnotic, such as propofol, thiopentone, or isoflurane, for the induction of anaesthesia. Administering remifentanil after a hypnotic will reduce the incidence of muscle rigidity. Remifentanil can be administered at an infusion rate of 0.5 to 1 micrograms/kg/min, with or without an initial bolus injection of 1 micrograms/kg given over not less than 30 seconds. If endotracheal intubation is to occur more than 8 to 10 minutes after the start of the infusion of remifentanil, then a bolus injection is not necessary.
\*Maintenance of anaesthesia in ventilated patients\*
After endotracheal intubation, the infusion rate of remifentanil should be decreased, according to anaesthetic technique, as indicated in the above table. Due to the fast onset and short duration of action of remifentanil, the rate of administration during anaesthesia can be titrated upward in 25 % to 100 % increments or downward in 25 % to 50 % decrements, every 2 to 5 minutes to attain the desired level of μ-opioid response. In response to light anaesthesia, supplemental bolus injections may be administered every 2 to 5 minutes.
\*Anaesthesia in spontaneously breathing anaesthetised patients with a secured airway (e.g. laryngeal mask anaesthesia)\*
In spontaneously breathing anaesthetised patients with a secured airway respiratory depression is likely to occur. Therefore attention must be given to respiratory effects possibly combined with muscular rigidity. Special care is needed to adjust the dose to the patient requirements and ventilatory support may be required. Adequate facilities should be available for monitoring of patients administered remifentanil. It is essential that these facilities be fully equipped to handle all degrees of respiratory depression (intubation equipment must be available) and/or muscle rigidity (for more information see section 4.4).
The recommended starting infusion rate for supplemental analgesia in spontaneously breathing anaesthetised patients is 0.04 micrograms/kg/min with titration to effect. A range of infusion rates from 0.025 to 0.1 micrograms/kg/min has been studied.
Bolus injections are not recommended in spontaneously breathing anaesthetised patients.
\*Concomitant medicinal products\*
Remifentanil decreases the amounts or doses of inhalational anaesthetics, hypnotics and benzodiazepines required for anaesthesia (see section 4.5).
Doses of the following medicinal products used in anaesthesia have been reduced by up to 75 % when used concurrently with remifentanil: isoflurane, thiopentone, propofol, midazolam and temazepam.
\*Guidelines for discontinuation in the immediate postoperative period\*
Due to the very rapid offset of action of remifentanil no residual opioid activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of post-operative care.
If the longer acting analgesic has not reached the appropriate effect before the end of surgery, the administration of remifentanil may need to be continued to maintain analgesia during immediate post-operative period until longer acting analgesic has reached the maximum effect.
It is recommended that patients should be closely monitored post-operatively for pain, hypotension and bradycardia.
Further information about the administration in mechanically ventilated intensive care patients is given in section 4.2.3.
In spontaneously breathing patients the initial infusion rate of remifentanil may be decreased to 0.1 micrograms/kg/min and thereafter can be increased or decreased every 5 min in steps of 0.025 micrograms/kg/min to balance the extent of analgesia against the degree of respiratory depression.
In spontaneously breathing patients bolus doses for analgesia are not recommended during the postoperative period.
\*\*\*Administration by Target-Controlled Infusion (TCI)\*\*\*
\*Induction and maintenance of anaesthesia in ventilated patients\*
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic during the induction and maintenance of anaesthesia in ventilated adult patients (see table 1 above for manually controlled infusion). In association with these medicinal products, adequate analgesia for induction of anaesthesia and surgery can generally be achieved with target blood remifentanil concentrations ranging from 3 to 8 nanograms/ml. Remifentanil should be titrated to individual patient response. For particularly stimulating surgical procedures target blood concentrations up to 15 nanograms/ml may be required.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil (see table 1 above for manually controlled infusion)\*.\*
The following table provides the equivalent blood remifentanil concentration using a TCI approach for various manually controlled infusion rates at steady state:
\*Table 2: Remifentanil blood concentrations (nanograms/ml) estimated using the Minto (1997) pharmacokinetic model in a 70 kg, 170 cm, 40 year old male patient for various manually controlled infusion rates (micrograms/kg/min) at steady state\*
| | |
| --- | --- |
| \*\*Remifentanil Infusion Rate\*\* \*\*(micrograms/kg/min)\*\* | \*\*Remifentanil Blood Concentration\*\* \*\*(nanograms/ml)\*\* |
| 0.05 | 1.3 |
| 0.10 | 2.6 |
| 0.25 | 6.3 |
| 0.40 | 10.4 |
| 0.50 | 12.6 |
| 1.0 | 25.2 |
| 2.0 | 50.5 |
As there are insufficient data, the administration of remifentanil by TCI for spontaneous ventilation anaesthesia is not recommended.
\*Guidelines for discontinuation/continuation in the immediate post-operative period\*
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see also \*Guidelines for discontinuation / continuation during immediate postoperative period\* in the section above for \*\*\*Administration by Manually Controlled Infusion (MCI)\*\*\*).
As there are insufficient data, the administration of remifentanil by TCI for the management of post-operative analgesia is not recommended.
\*\*4.2.1.2 Paediatric patients (1 to12 years of age)\*\*
Co-administration of remifentanil and an intravenous anaesthetic agent for induction of anaesthesia has not been studied in detail and is therefore not recommended.
Remifentanil TCI has not been studied in paediatric patients and therefore administration of remifentanil by TCI is not recommended in these patients.
\*Induction of anaesthesia\*
The use of remifentanil for induction of anaesthesia in patients aged 1 to 12 years is not recommended as there are no data available in this patient population.
\*Maintenance of anaesthesia\*
The following doses of remifentanil (see table 3) are recommended for maintenance of anaesthesia:
\*Table 3: Dosing Guideline for Paediatric Patients (1 to 12 years of age)\*
| | | | |
| --- | --- | --- | --- |
| \*\*CONCOMITANT ANAESTHETIC\\*\*\* | \*\*REMIFENTANILBOLUS INJECTION\*\* \*\*(micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*(micrograms/kg/min)\*\* | |
| \*\*Starting Rate\*\* | \*\*Maintenance Rate\*\* |
| Halothane (starting dose 0.3 MAC) | 1 | 0.25 | 0.05 to 1.3 |
| Sevoflurane (starting dose 0.3 MAC) | 1 | 0.25 | 0.05 to 0.9 |
| Isoflurane (starting dose 0.5 MAC) | 1 | 0.25 | 0.06 to 0.9 |
\\*co-administered with nitrous oxide / oxygen in a ratio of 2:1
When given by bolus injection remifentanil should be administered \*\*over not less than 30 seconds\*\*. Surgery should not commence until at least 5 minutes after the start of the remifentanil infusion, if a simultaneous bolus dose has not been given.
For sole administration of nitrous oxide (70 %) with remifentanil, infusion rates for maintenance of anaesthesia should be between 0.4 and 3 micrograms/kg/min. Data gained from adults suggest that 0.4 micrograms/kg/min may be a convenient initial dose although specific studies are lacking.
Paediatric patients should be monitored and the dose titrated to the depth of analgesia appropriate for the surgical procedure.
\*Concomitant medicinal products\*
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic required to maintain anaesthesia. Therefore, isoflurane, halothane and sevoflurane should be administered as recommended above to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil.
No conclusive data are available for dose recommendations for simultaneous use of other hypnotics with remifentanil. The dose and duration of concomitant use of benzodiazepines and related drugs should be limited to the lowest effective dose and treatment as short as possible (see above and sections 4.4 and 4.5).
\*Guidelines for patient management in the immediate post-operative period /\*
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual activity will be present within 5 to 10 minutes after discontinuation. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the therapeutic effect of the longer acting analgesic. The choice of medicinal product(s), the dose and the time of administration should be planned in advance and individually tailored to be appropriate for the patient's surgical procedure and the level of post-operative care anticipated (see section 4.4).
\*\*4.2.1.3 Neonates/infants (aged less than 1 year)\*\*
There is limited experience of remifentanil in newborn infants and infants (aged under 1 year old; see section 5.1). The pharmacokinetic profile of remifentanil in newborn infants and infants (aged less than 1 year) is comparable to that seen in adults after correction for body weight differences (see section 5.2). However, because there are insufficient clinical data, the administration of remifentanil is not recommended for this age group.
Use for Total Intravenous anaesthesia (TIVA): There is limited clinical trial experience of remifentanil for TIVA in infants (see section 5.1). However, there are insufficient clinical data to make dose recommendations.
\*\*4.2.1.4 Special patient groups\*\*
For dose recommendations for special patient groups (elderly and obese patients, renally and hepatically impaired patients, patients undergoing neurosurgery and ASA III/IV patients; see section 4.2.4).
\*\*\*\*4.2.2 Cardiac anaesthesia\*\*\*\*
\*Administration by Manually Controlled Infusion (MCI)\*
For dose recommendations in patients undergoing cardiac surgery see table 4 below:
\*Table 4: Dosing Guidelines for Cardiac Anaesthesia:\*
| | | | |
| --- | --- | --- | --- |
| \*\*INDICATION\*\* | \*\*REMIFENTANIL BOLUS INJECTION\*\* \*\*(micrograms/kg)\*\* | \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*(micrograms/kg/min)\*\* | |
| \*\*Starting Rate\*\* | \*\*Typical infusion Rates\*\* |
| \*\*Induction of anaesthesia\*\* | Not recommended | 1 | \\_ |
| \*\*Maintenance of anaesthesia in ventilated patients\*\* | | | |
| • Isoflurane (starting dose 0.4 MAC) | 0.5 to 1 | 1 | 0.003 to 4 | |
| • Propofol (starting dose 50 micrograms/kg/min) | 0.5 to 1 | 1 | 0.01 to 4.3 | |
| \*\*Continuation of post-operative analgesia, prior to extubation\*\* | Not recommended | 1 | 0 to 1 | |
\*Induction period of anaesthesia\*
After administration of a hypnotic to achieve loss of consciousness, remifentanil should be administered at an initial infusion rate of 1 microgram/kg/min. The use of bolus injections of remifentanil during induction in cardiac surgical patients is not recommended. Endotracheal intubation should not occur until at least 5 minutes after the start of the infusion.
\*Maintenance period of anaesthesia\*
After endotracheal intubation the infusion rate of remifentanil can be titrated upward in 25% to 100% increments, or downward in 25% to 50% decrements, every 2 to 5 minutes according to patient need. Supplemental slow bolus doses, administered over not less than 30 seconds, may also be given every 2 to 5 minutes as required. High risk cardiac patients, such as those undergoing valve surgery or with poor left ventricular function, should be administered a maximum bolus dose of 0.5 micrograms/kg. These dosing recommendations also apply during hypothermic cardiopulmonary bypass (see section 5.2).
\*Concomitant medicinal products\*
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid excessive depth of anaesthesia.
No data are available for dose recommendations for simultaneous use of other hypnotics with remifentanil (see in section above: \*Administration by Manually Controlled Infusion (MCI), Concomitant medicinal products\*).
\*Guidelines for postoperative patient management\*
\*Continuation of post-operative analgesia with remifentanil prior to extubation\*
It is recommended that the infusion of remifentanil should be maintained at the final intra-operative rate during transfer of patients to the post-operative care area. Upon arrival into this area, the patient's level of analgesia and sedation should be closely monitored and the remifentanil infusion rate adjusted to meet the individual patient's requirements (for further information on management of intensive care patients see section 4.2.3).
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation. Prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established. It is therefore recommended that the choice of medicinal product(s), the dose and the time of administration are planned before weaning the patient from the ventilator.
\*Guidelines for discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, hypertension, shivering and pain have been reported in cardiac patients immediately following discontinuation of remifentanil (see section 4.8). To minimise the risk of these occurring, adequate alternative analgesia must be established (as described above), before the remifentanil infusion is discontinued. The infusion rate should be reduced by 25 % decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator the remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics. Haemodynamic changes such as hypertension and tachycardia should be treated with alternative medicinal products as appropriate.
\*\*When other opioid agents are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these agents.\*\*
\*\*\*Administration by Target-Controlled Infusion\*\*\*
\*Induction and maintenance of anaesthesia\*
Remifentanil TCI should be used in association with an intravenous or inhalational hypnotic agent during the induction and maintenance of anaesthesia in ventilated adult patients (see \*Table 4\*: \*Dosing Guidelines for Cardiac Anaesthesia in section 4.2.2\*). In association with these agents, adequate analgesia for cardiac surgery is generally achieved at the higher end of the range of target blood remifentanil concentrations used for general surgical procedures. Following titration of remifentanil to individual patient response, blood concentrations as high as 20 nanograms/ml have been used in clinical studies.
At the doses recommended above, remifentanil significantly reduces the amount of hypnotic agent required to maintain anaesthesia. Therefore, isoflurane and propofol should be administered as recommended above to avoid an increase of haemodynamic effects (hypotension and bradycardia) of remifentanil (see \*Table 4\*: \*Dosing Guidelines for Cardiac Anaesthesia above\*).
For information on blood remifentanil concentrations achieved with manually controlled infusion see \*Table 2\*: \*Remifentanil Blood Concentrations (nanograms/ml) estimated using the Minto Model (1997)\* in section 4.2.1.1)\*.\*
\*Guidelines for discontinuation / continuation in the immediate post-operative period\*
At the end of surgery when the TCI infusion is stopped or the target concentration reduced, spontaneous respiration is likely to return at calculated remifentanil concentrations in the region of 1 to 2 nanograms/ml. As with manually controlled infusion, post-operative analgesia should be established before the end of surgery with longer acting analgesics (see \*Guidelines for discontinuation\* \*in the immediate post-operative period\* in section 4.2.1.1).
As there are insufficient data, the administration of remifentanil by TCI for the management of post-operative analgesia is not recommended.
\*\*\*\*4.2.3 Use in intensive care\*\*\*\*
\*\*4.2.3.1 Adults\*\*
Remifentanil can be used for the provision of analgesia in mechanically ventilated intensive care patients. If required, additionally sedating medicinal products should be applied.
Remifentanil has been studied in mechanically ventilated intensive care patients in well controlled clinical trials for up to three days. As patients were not studied beyond three days, no evidence of safety and efficacy for longer treatment has been established. Therefore, the use of remifentanil is not recommended for a duration of treatment greater than three days.
Due to the lack of data the administration of remifentanil by TCI is not recommended for ICU patients.
In adults, it is recommended that remifentanil is initiated at an infusion rate of 0.1 micrograms/kg/min (6 micrograms/kg/h) to 0.15 micrograms/kg/min (9 micrograms/kg/h). The infusion rate should be titrated in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) to achieve the desired level of sedation and analgesia. A period of at least 5 minutes should be allowed between dose adjustments. The level of sedation and analgesia should be carefully monitored, regularly reassessed and the remifentanil infusion rate adjusted accordingly. If an infusion rate of 0.2 micrograms/kg/min (12 micrograms/kg/h) is reached and the desired level of sedation is not achieved, it is recommended that dosing with an appropriate sedative is initiated (see below). The dose of sedative should be titrated to obtain the desired level of sedation. Further increases to the remifentanil infusion rate in increments of 0.025 micrograms/kg/min (1.5 micrograms/kg/h) may be made if additional analgesia is required.
The following table summarises the starting infusion rates and typical dose range for provision of analgesia and sedation in individual patients:
\*Table 5: Dosing Guidelines for use of remifentanil within the intensive care setting\*
| | |
| --- | --- |
| \*\*CONTINUOUS REMIFENTANIL INFUSION\*\* \*\*micrograms/kg/min (micrograms/kg/h)\*\* | |
| \*\*Starting Rate\*\* | \*\*Range\*\* |
| 0.1 (6) to 0.15 (9) | 0.006 (0.36) to 0.74 (44.4) |
Bolus doses of remifentanil are not recommended in the intensive care setting.
The use of remifentanil will reduce the dose requirement of any concomitant sedative medicinal products. Typical starting doses for sedative medicinal products, if required, are given below:
\*Table 6: Recommended starting dose of sedative medicinal products, if required\*
| | | |
| --- | --- | --- |
| \*\*Sedative medicinal product\*\* | \*\*Bolus\*\* \*\*(mg/kg)\*\* | \*\*Infusion rate (mg/kg/h)\*\* |
| Propofol | Up to 0.5 | 0.5 |
| Midazolam | Up to 0.03 | 0.03 |
To allow separate titration of the respective medicinal products, sedative medicinal products should not be administered as an admixture.
\*Additional analgesia for ventilated patients undergoing painful procedures\*
An increase in the existing remifentanil infusion rate may be required to provide additional analgesic cover for ventilated patients undergoing stimulating and/or painful procedures such as endotracheal suctioning, wound dressing and physiotherapy. It is recommended that a remifentanil infusion rate of at least 0.1 micrograms/kg/min (6 micrograms/kg/h) should be maintained for at least 5 minutes prior to the start of the stimulating procedure. Further dose adjustments may be made every 2 to 5 minutes in increments of 25 %-50 % in anticipation of, or in response to, additional requirement for analgesia. A mean infusion rate of 0.25 micrograms/kg/min (15 micrograms/kg/h), maximum 0.75 micrograms/kg/min (45 micrograms/kg/h), has been administered for provision of additional analgesia during painful and stimulating procedures.
\*Establishment of alternative analgesia prior to discontinuation of remifentanil\*
Due to the very rapid offset of action of remifentanil, no residual opioid activity will be present within 5 to 10 minutes after discontinuation regardless of the duration of infusion. After administration of remifentanil the potential for the development of tolerance and hyperalgesia should be considered. Therefore, prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established and to prevent hyperalgesia and concomitant haemodynamic changes. It is therefore recommended that the choice of medicinal product(s), the dose and the time of administration are planned prior to discontinuation of remifentanil. Long acting or intravenous or local analgesics, which can be controlled by the health care staff or the patient, are alternative options for analgesia and should be chosen carefully according to the patient's needs.
Prolonged administration of µ-opioid agonists may induce development of tolerance.
\*\*\*Guidelines for extubation and discontinuation of remifentanil\*\*\*
In order to ensure a smooth emergence from a remifentanil-based regimen it is recommended that the infusion rate of remifentanil is titrated in stages to 0.1 micrograms/kg/min (6 micrograms/kg/h) over a period up to 1 hour prior to extubation.
Following extubation, the infusion rate should be reduced by 25 % decrements in at least 10-minute intervals until the infusion is discontinued. During weaning from the ventilator, the remifentanil infusion should not be increased and only down titration should occur, supplemented as required with alternative analgesics.
Upon discontinuation of remifentanil, the IV cannula should be cleared or removed to prevent subsequent inadvertent administration.
\*\*When other opioid medicinal products are administered as part of the regimen for transition to alternative analgesia, the patient must be carefully monitored. The benefit of providing adequate analgesia must always be balanced against the potential risk of respiratory depression with these medicinal products.\*\*
\*\*4.2.3.2 Paediatric intensive care patients\*\*
The use of remifentanil in intensive care patients under the age of 18 years is not recommended as there are no data available in this patient population.
\*\*4.2.3.3 Renally impaired intensive care patients\*\*
No adjustments to the doses recommended above are necessary in renally-impaired patients, including those undergoing renal replacement therapy, however the clearance of carboxylic acid metabolite is reduced in patients with impaired renal function (see section 5.2).
\*\*\*\*4.2.4 Special populations\*\*\*\*
\*\*4.2.4.1 Elderly (over 65 years of age)\*\*
\*General anaesthesia\*
Caution should be exercised in the administration of remifentanil in this population.
The initial starting dose of remifentanil administered to patients over 65 should be half the recommended adult dose and then titrated to the individual patient's need as an increased sensitivity to the pharmacodynamic effects of remifentanil has been seen in this patient population. This dose adjustment refers to application during all phases of anaesthesia including induction, maintenance and immediate post-operative analgesia.
Because of the increased sensitivity of elderly patients to remifentanil, when administering remifentanil by TCI in this population the initial target concentration should be 1.5 to 4 nanograms/ml with subsequent titration according to the individual patient's response.
\*Anaesthesia during cardiac surgery\*
Reduction of initial dose is not required (see section 4.2.2).
\*Intensive care\*
Reduction of initial dose is not required (see section 4.2.3 \*\*\*Intensive Care\*\*\* above).
\*\*4.2.4.2 Obese patients\*\*
For manually controlled infusion it is recommended that for obese patients the dose of remifentanil should be reduced and based upon ideal body weight as the clearance and volume of distribution of remifentanil are better correlated with ideal body weight than actual body weight.
With the calculation of lean body mass (LBM) used in the Minto model, LBM is likely to be underestimated in female patients with a body mass index (BMI) greater than 35 kg/m2 and in male patients with BMI greater than 40 kg/m2. To avoid underdosing in these patients, remifentanil TCI should be titrated carefully to individual response.
\*\*4.2.4.3 Renally impaired patients\*\*
On the basis of investigations carried out to date, a dose adjustment in patients with impaired renal function, including intensive care patients, is not necessary; however, these patients exhibit reduced clearance of carboxylic acid metabolite.
\*\*4.2.4.4 Patients with hepatic impairment\*\*
No adjustment of the initial dose, relative to that used in healthy adults, is necessary as the pharmacokinetic profile of remifentanil is unchanged in this patient population. However, patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil (see section 4.4). These patients should be closely monitored and the dose of remifentanil titrated to individual patient need.
\*\*4.2.4.5 Neurosurgery patients\*\*
Limited clinical experience in patients undergoing neurosurgery has shown that no special dose recommendations are required.
\*\*4.2.4.6 ASA III/IV patients\*\*
\*General anaesthesia\*
As the haemodynamic effects of potent opioids can be expected to be more pronounced in ASA III/IV patients, caution should be exercised in the administration of remifentanil in this population. Initial dose reduction and subsequent titration to effect is therefore recommended.
Data material is not conclusive for the application of remifentanil in paediatric ASA III/IV patients and therefore dose recommendations are not given.
For TCI, a lower initial target of 1.5 to 4 nanograms/ml should be used in ASA III or IV patients and subsequently titrated to response.
\*Cardiac anaesthesia\*
No initial dose reduction is required (see section 4.2.2).
\*\*\*\*4.2.5 Guidelines for remifentanil infusion rates for manually controlled infusion (MCI)\*\*\*\*
\*\*\*Table 7: Remifentanil infusion rates (ml/kg/h)\*\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Drug Delivery Rate\*\* | \*\*Infusion Rate (ml/kg/h) for solutions with concentrations of\*\* | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*20 micrograms/ml\*\* | \*\*25 micrograms/ml\*\* | \*\*50 micrograms/ml\*\* | \*\*250 micrograms/ml\*\* |
| \*\*1mg/50ml\*\* | \*\*1mg/40ml\*\* | \*\*1mg/20ml\*\* | \*\*10mg/40ml\*\* |
| \*\*0.0125\*\* | 0.038 | 0.03 | 0.015 | Not recommended |
| \*\*0.025\*\* | 0.075 | 0.06 | 0.03 | Not recommended |
| \*\*0.05\*\* | 0.15 | 0.12 | 0.06 | 0.012 |
| \*\*0.075\*\* | 0.23 | 0.18 | 0.09 | 0.018 |
| \*\*0.1\*\* | 0.3 | 0.24 | 0.12 | 0.024 |
| \*\*0.15\*\* | 0.45 | 0.36 | 0.18 | 0.036 |
| \*\*0.2\*\* | 0.6 | 0.48 | 0.24 | 0.048 |
| \*\*0.25\*\* | 0.75 | 0.6 | 0.3 | 0.06 |
| \*\*0.5\*\* | 1.5 | 1.2 | 0.6 | 0.12 |
| \*\*0.75\*\* | 2.25 | 1.8 | 0.9 | 0.18 |
| \*\*1.0\*\* | 3.0 | 2.4 | 1.2 | 0.24 |
| \*\*1.25\*\* | 3.75 | 3.0 | 1.5 | 0.3 |
| \*\*1.5\*\* | 4.5 | 3.6 | 1.8 | 0.36 |
| \*\*1.75\*\* | 5.25 | 4.2 | 2.1 | 0.42 |
| \*\*2.0\*\* | 6.0 | 4.8 | 2.4 | 0.48 |
\*\*\*Table 8: Remifentanil infusion rates (ml/h) for a 20 micrograms/ml solution\*\*\*
| | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*5\*\* | \*\*10\*\* | \*\*20\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* |
| \*\*0.0125\*\* | 0.188 | 0.375 | 0.75 | 1.125 | 1.5 | 1.875 | 2.25 |
| \*\*0.025\*\* | 0.375 | 0.75 | 1.5 | 2.25 | 3.0 | 3.75 | 4.5 |
| \*\*0.05\*\* | 0.75 | 1.5 | 3.0 | 4.5 | 6.0 | 7.5 | 9.0 |
| \*\*0.075\*\* | 1.125 | 2.25 | 4.5 | 6.75 | 9.0 | 11.25 | 13.5 |
| \*\*0.1\*\* | 1.5 | 3.0 | 6.0 | 9.0 | 12.0 | 15.0 | 18.0 |
| \*\*0.15\*\* | 2.25 | 4.5 | 9.0 | 13.5 | 18.0 | 22.5 | 27.0 |
| \*\*0.2\*\* | 3.0 | 6.0 | 12.0 | 18.0 | 24.0 | 30.0 | 36.0 |
| \*\*0.25\*\* | 3.75 | 7.5 | 15.0 | 22.5 | 30.0 | 37.5 | 45.0 |
| \*\*0.3\*\* | 4.5 | 9.0 | 18.0 | 27.0 | 36.0 | 45.0 | 54.0 |
| \*\*0.35\*\* | 5.25 | 10.5 | 21.0 | 31.5 | 42.0 | 52.5 | 63.0 |
| \*\*0.4\*\* | 6.0 | 12.0 | 24.0 | 36.0 | 48.0 | 60.0 | 72.0 |
\*\*\*Table 9: Remifentanil infusion rates (ml/h) for a 25 micrograms/ml solution\*\*\*
| | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*10\*\* | \*\*20\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.0125\*\* | 0.3 | 0.6 | 0.9 | 1.2 | 1.5 | 1.8 | 2.1 | 2.4 | 2.7 | 3.0 |
| \*\*0.025\*\* | 0.6 | 1.2 | 1.8 | 2.4 | 3.0 | 3.6 | 4.2 | 4.8 | 5.4 | 6.0 |
| \*\*0.05\*\* | 1.2 | 2.4 | 3.6 | 4.8 | 6.0 | 7.2 | 8.4 | 9.6 | 10.8 | 12.0 |
| \*\*0.075\*\* | 1.8 | 3.6 | 5.4 | 7.2 | 9.0 | 10.8 | 12.6 | 14.4 | 16.2 | 18.0 |
| \*\*0.1\*\* | 2.4 | 4.8 | 7.2 | 9.6 | 12.0 | 14.4 | 16.8 | 19.2 | 21.6 | 24.0 |
| \*\*0.15\*\* | 3.6 | 7.2 | 10.8 | 14.4 | 18.0 | 21.6 | 25.2 | 28.8 | 32.4 | 36.0 |
| \*\*0.2\*\* | 4.8 | 9.6 | 14.4 | 19.2 | 24.0 | 28.8 | 33.6 | 38.4 | 43.2 | 48.0 |
\*\*\*Table 10: Remifentanil infusion rates (ml/h) for a 50 micrograms/ml solution\*\*\*
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.025\*\* | 0.9 | 1.2 | 1.5 | 1.8 | 2.1 | 2.4 | 2.7 | 3.0 |
| \*\*0.05\*\* | 1.8 | 2.4 | 3.0 | 3.6 | 4.2 | 4.8 | 5.4 | 6.0 |
| \*\*0.075\*\* | 2.7 | 3.6 | 4.5 | 5.4 | 6.3 | 7.2 | 8.1 | 9.0 |
| \*\*0.1\*\* | 3.6 | 4.8 | 6.0 | 7.2 | 8.4 | 9.6 | 10.8 | 12.0 |
| \*\*0.15\*\* | 5.4 | 7.2 | 9.0 | 10.8 | 12.6 | 14.4 | 16.2 | 18.0 |
| \*\*0.2\*\* | 7.2 | 9.6 | 12.0 | 14.4 | 16.8 | 19.2 | 21.6 | 24.0 |
| \*\*0.25\*\* | 9.0 | 12.0 | 15.0 | 18.0 | 21.0 | 24.0 | 27.0 | 30.0 |
| \*\*0.5\*\* | 18.0 | 24.0 | 30.0 | 36.0 | 42.0 | 48.0 | 54.0 | 60.0 |
| \*\*0.75\*\* | 27.0 | 36.0 | 45.0 | 54.0 | 63.0 | 72.0 | 81.0 | 90.0 |
| \*\*1.0\*\* | 36.0 | 48.0 | 60.0 | 72.0 | 84.0 | 96.0 | 108.0 | 120.0 |
| \*\*1.25\*\* | 45.0 | 60.0 | 75.0 | 90.0 | 105.0 | 120.0 | 135.0 | 150.0 |
| \*\*1.5\*\* | 54.0 | 72.0 | 90.0 | 108.0 | 126.0 | 144.0 | 162.0 | 180.0 |
| \*\*1.75\*\* | 63.0 | 84.0 | 105.0 | 126.0 | 147.0 | 168.0 | 189.0 | 210.0 |
| \*\*2.0\*\* | 72.0 | 96.0 | 120.0 | 144.0 | 168.0 | 192.0 | 216.0 | 240.0 |
\*\*\*Table 11: Remifentanil infusion rates (ml/h) for a 250 micrograms/ml solution\*\*\*
| | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| \*\*Infusion Rate\*\* | \*\*Patient Weight (kg)\*\* | | | | | | | |
| \*\*(micrograms/kg/min)\*\* | \*\*30\*\* | \*\*40\*\* | \*\*50\*\* | \*\*60\*\* | \*\*70\*\* | \*\*80\*\* | \*\*90\*\* | \*\*100\*\* |
| \*\*0.1\*\* | 0.72 | 0.96 | 1.20 | 1.44 | 1.68 | 1.92 | 2.16 | 2.40 |
| \*\*0.15\*\* | 1.08 | 1.44 | 1.80 | 2.16 | 2.52 | 2.88 | 3.24 | 3.60 |
| \*\*0.2\*\* | 1.44 | 1.92 | 2.40 | 2.88 | 3.36 | 3.84 | 4.32 | 4.80 |
| \*\*0.25\*\* | 1.80 | 2.40 | 3.00 | 3.60 | 4.20 | 4.80 | 5.40 | 6.00 |
| \*\*0.5\*\* | 3.60 | 4.80 | 6.00 | 7.20 | 8.40 | 9.60 | 10.80 | 12.00 |
| \*\*0.75\*\* | 5.40 | 7.20 | 9.00 | 10.80 | 12.60 | 14.40 | 16.20 | 18.00 |
| \*\*1.0\*\* | 7.20 | 9.60 | 12.00 | 14.40 | 16.80 | 19.20 | 21.60 | 24.00 |
| \*\*1.25\*\* | 9.00 | 12.00 | 15.00 | 18.00 | 21.00 | 24.00 | 27.00 | 30.00 |
| \*\*1.5\*\* | 10.80 | 14.40 | 18.00 | 21.60 | 25.20 | 28.80 | 32.40 | 36.00 |
| \*\*1.75\*\* | 12.60 | 16.80 | 21.00 | 25.20 | 29.40 | 33.60 | 37.80 | 42.00 |
| \*\*2.0\*\* | 14.40 | 19.20 | 24.00 | 28.80 | 33.60 | 38.40 | 43.20 | 48.00 |
\*\*Method of administration\*\*
Remifentanil is intended for intravenous use only and must not be administered as an epidural or intrathecal injection (see section 4.3).
Continuous infusions of remifentanil must be administered by a calibrated infusion device into a fast flowing IV line or via a dedicated IV line. This infusion line should be connected at, or close to, the venous cannula and primed, to minimise the potential dead space (see section 4.2.5 for tables with examples of infusion rates by body weight to help titrate remifentanil to the patient`s anaesthetic needs).
Care should be taken to avoid obstruction or disconnection of infusion lines and to adequately clear the lines to remove residual remifentanil after use (see section 4.4). IV lines/infusion systems should be removed after cessation of use to avoid inadvertent administration.
Remifentanil may also be given by target-controlled infusion (TCI) with an approved infusion device incorporating the Minto pharmacokinetic model with covariates for age and lean body mass (LBM).
After reconstitution of the lyophilized powder, remifentanil must not be administered without further dilution.
For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.4.3 Contraindications
Hypersensitivity to the active substance, to other fentanyl analogues or to any of the excipients listed in section 6.1.
Remifentanil is contra-indicated for use as the sole medicinal product for induction of anaesthesia.
As glycine is present in the formulation, Remifentanil is contraindicated for epidural and intrathecal use (see section 5.3).4.4 Special warnings and precautions for use
Remifentanil should be administered only in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function, and by persons specifically trained in the use of anaesthetic medicinal products and the recognition and management of the expected undesirable effects of potent opioids, including respiratory and cardiac resuscitation. Such training must include the establishment and maintenance of a patent airway and assisted ventilation.
The use of remifentanil in mechanically ventilated intensive care patients is not recommended for a duration of treatment greater than 3 days.
Patients with a known hypersensitivity to opioids of a different class may exhibit a hypersensitivity reaction following administration of remifentanil. Caution should be exercised before using remifentanil in these patients.
Remifentanil should not be used as an analgesic in procedures where patients remain conscious or do not receive any airway support during the procedure.
\*\*Rapid offset of action/transition to alternative analgesia\*\*
Due to the very rapid offset of action of remifentanil, patients may emerge rapidly from anaesthesia and no residual opioid activity will be present within 5-10 minutes after the discontinuation of remifentanil. For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. During administration of remifentanil as a μ-opioid agonist the potential for the development of tolerance, hyperalgesia and associated haemodynamic changes should be considered. Therefore, prior to discontinuation of remifentanil, patients must be given alternative analgesic and sedative medicinal products at a sufficient time in advance to allow the therapeutic effects of these medicinal products to become established and to prevent hyperalgesia and concomitant haemodynamic changes.
For those patients undergoing surgical procedures where post-operative pain is anticipated, analgesics should be administered prior to discontinuation of remifentanil. Sufficient time must be allowed to reach the maximum effect of the longer acting analgesic. The choice of analgesic should be appropriate for the patient's surgical procedure and the level of post-operative care.
When other opioid medicinal products are administered as part of the regimen for transition to alternative analgesia, the benefit of providing adequate post-operative analgesia must always be balanced against the potential risk of respiratory depression with these medicinal products.
\*\*Risk from concomitant use of sedative medicinal products such as benzodiazepines or related medicinal products\*\*
Concomitant use of Remifentanil and sedative medicinal products such as benzodiazepines or related medicinal products may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Remifentanil concomitantly with sedative medicinal products, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
\*\*Tolerance and opioid use disorder (abuse and dependence)\*\*
Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids. Abuse or intentional misuse of opioids may result in overdose and/or death. The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).
\*\*Discontinuation of treatment and withdrawal syndrome\*\*
Repeated administration at short term intervals for prolonged periods may result in the development of withdrawal syndrome after cessation of therapy. Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported infrequently upon abrupt cessation, particularly after prolonged administration of more than 3 days. Where reported, re-introduction and tapering of the infusion has been beneficial. The use of remifentanil in mechanically ventilated intensive care patients is not recommended for duration of treatment greater than 3 days.
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with remifentanil.
To minimise symptoms of withdrawal tapering from a high dose may take weeks to months.
Additional to the symptoms mentioned above the opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, or increased respiratory rate.
\*\*Muscle rigidity - prevention and management\*\*
At the doses recommended muscle rigidity may occur. The incidence of muscle rigidity is related to the dose and rate of administration. Therefore, bolus injections should be administered over not less than 30 seconds.
Muscle rigidity induced by remifentanil must be treated in the context of the patient's clinical condition with appropriate supporting measures including ventilatory support. Excessive muscle rigidity occurring during the induction of anaesthesia should be treated by the administration of a neuromuscular blocking medicinal product and/or additional hypnotics. Muscle rigidity seen during the use of remifentanil as an analgesic may be treated by stopping or decreasing the rate of administration of remifentanil. Resolution of muscle rigidity after discontinuing the infusion of remifentanil occurs within minutes. Alternatively, a µ-opioid antagonist may be administered; however, this may reverse or attenuate the analgesic effect of remifentanil.
\*\*Hyperalgesia\*\*
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
\*\*Respiratory depression – preventive measures and treatment\*\*
Profound analgesia is accompanied by marked respiratory depression. Therefore, remifentanil should only be used in areas where facilities for monitoring and dealing with respiratory depression are available. Special care should be taken in patients with impaired lung function and with severe hepatic impairment. These patients may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil titrated to individual patient need.
The appearance of respiratory depression should be managed appropriately, including decreasing the rate of infusion by 50 %, or by a temporary discontinuation of the infusion. Remifentanil has not been shown to cause recurrent respiratory depression even after prolonged administration. However, in the presence of confounding factors (e.g. inadvertent administration of bolus doses (see section below) and administration of concomitant longer acting opioids), respiratory depression occurring up to 50 minutes after discontinuation of infusion has been reported. As many factors may affect post-operative recovery, it is important to ensure that full consciousness and adequate spontaneous ventilation are achieved before the patient is discharged from the recovery area.
\*\*Cardiovascular effects\*\*
Hypotension and bradycardia can give rise to asystole and cardiac arrest (see sections 4.5 and 4.8) may be managed by reducing the rate of infusion of remifentanil or the dose of concurrent anaesthetics or by using IV fluids, vasopressor or anticholinergic medicinal products as appropriate.
Debilitated, hypovolaemic, and elderly patients may be more sensitive to the cardiovascular effects of remifentanil.
\*\*Inadvertent administration\*\*
A sufficient amount of remifentanil may be present in the dead space of the IV line and/or cannula to cause respiratory depression, apnoea and/or muscle rigidity if the line is flushed with IV fluids or other medicinal products. This may be avoided by administering remifentanil into a fast flowing IV line or via a dedicated IV line which is removed when remifentanil is discontinued.
\*\*Neonates/infants\*\*
There is limited data available on use in newborn infants and infants under 1 year of age (see sections 4.2. and 5.1).4.5 Interaction with other medicinal products and other forms of interaction
Remifentanil is not metabolised by plasmacholinesterase, therefore, interactions with medicinal products metabolised by this enzyme are not anticipated.
Remifentanil, whether given by manually controlled infusion or TCI, decreases the amounts or doses of inhalational and IV anaesthetics, and benzodiazepines required for anaesthesia (see below and sections 4.2 and 4.4). If doses of concomitantly administered CNS depressant medicinal products are not reduced patients may experience an increased incidence of adverse effects associated with these medicinal products.
The cardiovascular effects of remifentanil (hypotension and bradycardia), may exacerbate in patients receiving concomitant cardiac depressant medicinal products, such as beta-blockers and calcium channel blocking medicinal products (see also sections 4.4 and 4.8).
If concomitant use of other serotonergic medicinal products is warranted, patients should be monitored for serotonin syndrome, particularly during initiation of therapy and dose increases. If serotonin syndrome is suspected, treatment with remifentanil, other opiate therapy, and/or any concurrently administered serotonergic medicinal products should be discontinued.
Sedative medicinal products such as benzodiazepines or related medicinal products:
The concomitant use of opioids with sedative medicinal products such as benzodiazepines or related medicinal products increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4). The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.
Co-administration of remifentanil with a serotonergic agent, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) or Monoamine Oxidase Inhibitors (MAOIs) may increase the risk of serotonin syndrome, a potentially life-threatening condition. Caution should be exercised with concomitant use of MAOIs. Irreversible MAOIs should be discontinued at least 2 weeks prior to remifentanil use.
After receiving remifentanil, it is advisable that alcoholic drink is avoided.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
There are no adequate and well-controlled studies in pregnant women.
Animal studies have shown reproductive toxicity (see section 5.3).
Remifentanil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
\*\*Labour and delivery\*\*
The safety profile of remifentanil during labour and delivery has not been researched. There are insufficient data to recommend remifentanil for use during labour and caesarean section. Remifentanil crosses the placental barrier, and fentanyl analogues can cause respiratory depression in the child. In case remifentanil is administered nevertheless, the patient and the neonate must be monitored for signs of excess sedation or respiratory depression (see section 4.4).
\*\*Breast-feeding\*\*
It is not known whether remifentanil is excreted in human breast milk. However, because fentanyl analogues are excreted in breast milk and remifentanil-related material was found in rat milk after dosing with remifentanil, breast-feeding mothers should be advised to discontinue breast-feeding for 24 hours following administration of remifentanil.
For a summary of the reproductive toxicity study findings please refer to Section 5.3 Preclinical safety data.4.7 Effects on ability to drive and use machines
Remifentanil has major influence on the ability to drive and use machines.
If an early discharge is envisaged after application of remifentanil, following treatment using anaesthetic medicinal products, patients should be advised not to drive or operate machinery. It is advisable that the patient is accompanied when returning home and that alcoholic drink is avoided.
This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and
o It was not affecting your ability to drive safely4.8 Undesirable effects
The most common undesirable effects associated with remifentanil are direct consequences of the effects of μ-opioid agonists. These undesirable effects resolve within minutes of discontinuing or decreasing the rate of remifentanil administration.
The following frequencies have been used in order to classify the occurrence of undesirable effects:
| | |
| --- | --- |
| Very common | ≥ 1/10 |
| Common | ≥ 1/100 to < 1/10 |
| Uncommon | ≥ 1/1,000 to < 1/100 |
| Rare | ≥ 1/10,000 to < 1/1,000 |
| Very rare | < 1/10,000 |
| not known (cannot be estimated from the available data) | |
Incidence is listed below within each system organ class:
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reactions\*\* |
| Immune system disorders | Rare | allergic reactions including anaphylaxis have been reported in patients receiving remifentanil in conjunction with one or more anaesthetic agents |
| Not known | anaphylactic shock |
| Psychiatric disorders | Not known | drug dependence (see section 4.4), withdrawal syndrome |
| Nervous system disorders | Very common | skeletal muscle rigidity |
| Rare | sedation (during awakening after general anaesthesia) |
| Not known | convulsions |
| Cardiac disorders | Common | bradycardia |
| Rare | asystole/cardiac arrest with preceding bradycardia in patients treated with remifentanil in combination with other anaesthetics |
| Not known | atrioventricular block, arrhythmia |
| Vascular disorders | Very common | hypotension |
| Common | post-operatively occurring hypertension |
| Respiratory, thoracic and mediastinal disorders | Common | acute respiratory depression, apnoea, cough |
| Uncommon | hypoxia |
| Gastrointestinal disorders | Very common | nausea, vomiting |
| Uncommon | constipation |
| Skin and subcutaneous tissue disorders | Common | pruritus |
| General disorders and administration site conditions | Common | post-operative shivering |
| Uncommon | post-operative pain |
| Not known | drug tolerance |
\*\*Discontinuation of treatment\*\*
Symptoms following withdrawal of remifentanil including tachycardia, hypertension and agitation have been reported rarely upon abrupt cessation, particularly after prolonged administration of more than 3 days (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
\*\*Symptoms\*\*
Overdose would be manifested by an extension of the pharmacologically predictable actions of remifentanil. Due to the very short duration of action of remifentanil, the potential for deleterious effects due to overdose is limited to the immediate time period following administration of the medicinal product. Response to discontinuation of the medicinal product is rapid, with return to baseline within ten minutes.
\*\*Management\*\*
In the event of overdose, or suspected overdose, the following actions should be taken: discontinue administration of remifentanil, a patent airway should be maintained, assisted or controlled ventilation with oxygen initiated, and adequate cardiovascular function maintained. If depressed respiration is associated with muscle rigidity, a neuromuscular blocking medicinal product may be required to facilitate assisted or controlled respiration. Intravenous fluids and vasopressor medicinal products may be administered for the treatment of hypotension. Other supportive measures may be useful.
Intravenous administration of an opioid antagonist such as naloxone may be indicated as a specific antidote in addition to ventilatory support to manage severe respiratory depression. The duration of respiratory depression following overdose with remifentanil is unlikely to exceed the duration of action of the opioid antagonist.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: anaesthetics, general; opioid anaesthetics
ATC-Code: N01AH06
Remifentanil is a selective μ-opioid agonist with a rapid onset and very short duration of action. The μ-opioid activity, of remifentanil, is antagonised by narcotic antagonists, such as naloxone.
Assays of histamine in patients and healthy volunteers have shown no elevation in histamine levels after administration of remifentanil in bolus doses up to 30 micrograms/kg.
\*\*Neonates/infants (aged less than 1 year)\*\*
In a randomised (ratio of 2:1, remifentanil:halothane), open label, parallel group, multicentre study in 60 young infants and newborn infants ≤8 weeks of age (mean 5.5 weeks) with an ASA physical status of I-II who were undergoing pyloromyotomy, the efficacy and safety of remifentanil (given as a 0.4 micrograms/kg/min initial continuous infusion plus supplemental doses or infusion rate changes as needed) was compared with halothane (given at 0.4% with supplemental increases as needed). Maintenance of anaesthesia was achieved by the additional administration of 70 % nitrous oxide (N2O) plus 30 % oxygen. Recovery times were superior in the remifentanil relative to the halothane groups (not significant).
\*\*Use for Total Intravenous anaesthesia (TIVA) - children aged 6 months to 16 years\*\*
TIVA with remifentanil in paediatric surgery was compared to inhalation anaesthesia in three randomised, open-label studies. The results are summarised in the table below.
| | | | |
| --- | --- | --- | --- |
| \*\*Surgical intervention\*\* | \*\*Age (y), (N)\*\* | \*\*Study condition (maintenance)\*\* | \*\*Extubation (min)\*\* \*\*(mean (SD))\*\* |
| Lower abdominal/urological surgery | 0.5-16 (120) | TIVA: propofol (5-10 mg/kg/h) + remifentanil (0.125-1.0 micrograms/kg/min) Inhalational anaesthesia: sevoflurane (1.0-1.5 MAC) + remifentanil (0.125-1.0 micrograms/kg/min) | 11.8 (4.2) 15.0 (5.6) (p<0.05) |
| ENT-surgery | 4-11 (50) | TIVA: propofol (3 mg/kg/h) + remifentanil (0.5 micrograms/kg/min) Inhalational anaesthesia: desflurane (1.3 MAC) + N2O mixture | 11 (3.7) 9.4 (2.9) not significant |
| General or ENT surgery | 2-12 (153) | TIVA: propofol (100-200 micrograms/kg/min) + remifentanil (0.2-0.5 micrograms/kg/min) Inhalational anaesthesia: sevoflurane (1.0-1.5 MAC) + N2O mixture | comparable extubation times (based on limited data) |
In the study in lower abdominal/urological surgery comparing remifentanil/propofol with remifentanil/sevoflurane, hypotension occurred significantly more often under remifentanil/sevoflurane, and bradycardia occurred significantly more often under remifentanil/propofol. In the study in ENT surgery comparing remifentanil/propofol with desflurane/nitrous oxide, a significantly higher heart rate was seen in subjects receiving desflurane/nitrous oxide compared with remifentanil/propofol and with baseline values.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
Blood concentrations of remifentanil are proportional to the dose administered throughout the recommended dose range. For every 0.1 micrograms/kg/min increase in i.v. infusion rate, the blood concentration of remifentanil will rise by 2.5 nanograms/ml.
\*\*Distribution\*\*
Remifentanil is approximately 70 % bound to plasma proteins.
The central volume of distribution is 100 ml/kg and the steady-state volume of distribution is 350 ml/kg.
\*\*Placental and breast milk transfer\*\*
In a human clinical trial, the average maternal remifentanil concentrations were approximately twice those seen in the foetus. In some cases, however, foetal concentrations were similar to those in the mother. The umbilical arteriovenous ratio of remifentanil concentrations was approximately 30 % suggesting metabolism of remifentanil in the neonate. Remifentanil related material is transferred to the milk of lactating rats.
\*\*Biotransformation\*\*
Remifentanil is an esterase metabolised opioid that is susceptible to metabolism by non-specific blood and tissue esterases. The metabolism of remifentanil results in the formation of an essentially inactive carboxylic acid metabolite (1/4600th as potent as remifentanil). Studies in man indicate that all pharmacological activity is associated with the parent compound. The activity of this metabolite is therefore not of any clinical relevance.
The half-life of the metabolite in healthy adults is 2 hours. Approximately 95 % of remifentanil as the carboxylic acid metabolite is recovered in the urine in patients with normal renal function.
Remifentanil is not a substrate for plasma cholinesterase.
\*\*Elimination\*\*
Following administration of the recommended doses of remifentanil, the effective biological half-life is 3-10 minutes.
The average clearance of remifentanil in young healthy adults is 40 ml/min/kg.
\*\*Special patient groups\*\*
\*\*Elderly patients\*\*
The clearance of remifentanil is slightly reduced (by approximately 25 %) in elderly patients (over 65 years of age) compared to that in young patients. The pharmacodynamic activity of remifentanil increases with increasing age. Elderly patients have a remifentanil EC50 for formation of delta waves on the electroencephalogram that is 50 % lower than young patients; therefore, the initial dose of remifentanil should be reduced by 50 % in elderly patients and then carefully titrated to meet the individual patient need.
\*\*Paediatric patients\*\*
The average clearance and steady state volume of distribution of remifentanil are increased in younger children and decline to young healthy adult values by age 17. The elimination half-life of remifentanil in newborn infants is not significantly different from that of young healthy adults. Changes in analgesic effect after changes in infusion rate of remifentanil should be rapid and similar to those seen in young healthy adults. The pharmacokinetics of the carboxylic acid metabolite in paediatric patients between 2 and 17 years of age are similar to those seen in adults after correcting for differences in body weight.
\*\*Cardiac anaesthesia\*\*
The clearance of remifentanil is reduced by approximately 20 % during hypothermic (28°C) cardiopulmonary bypass. A decrease in body temperature lowers elimination clearance by 3 % per degree centigrade.
\*\*Renal impairment\*\*
The rapid recovery from remifentanil-based sedation and analgesia is unaffected by renal status.
The pharmacokinetics of remifentanil are not significantly changed in patients with varying degrees of renal impairment even after administration for up to 3 days in the intensive care setting.
The clearance of the carboxylic acid metabolite is reduced in patients with renal impairment. In intensive care patients with moderate/severe renal impairment, the concentration of the carboxylic acid metabolite is expected to reach approximately 250-fold the level of remifentanil at steady-state. Clinical data demonstrate that the accumulation of the metabolite does not result in clinically relevant μ-opioid effects even after administration of remifentanil infusions for up to 3 days in these patients.
Up to now, data on safety and pharmacokinetic activity of metabolites after infusion of remifentanil for more than 3 days are lacking.
There is no evidence that remifentanil is extracted during renal replacement therapy.
25-30% of the carboxylic acid metabolite is extracted during haemodialysis. In patients with anuria the half-life of the carboxylic acid metabolite is increased to 30 hours.
\*\*Hepatic impairment\*\*
The pharmacokinetics of remifentanil are not changed in patients with severe hepatic impairment awaiting liver transplant, or during the anhepatic phase of liver transplant surgery. Patients with severe hepatic impairment may be slightly more sensitive to the respiratory depressant effects of remifentanil. These patients should be closely monitored and the dose of remifentanil should be titrated to the individual patient need.5.3 Preclinical safety data
Remifentanil, like some other fentanyl analogues, produced increases in action potential duration (APD) in dog isolated Purkinje fibres. After administration of remifentanil, effects were observed at concentrations of 1 micromolar and above (which are higher than plasma concentrations occurring in clinical practice). There were no effects at a remifentanil concentration of 0.1 micromolar. The main metabolite remifentanil acid showed no effect on the APD up to the maximum tested concentration of 10 micromolar.
\*\*Acute toxicity\*\*
Expected signs of μ-opioid intoxication were observed in non-ventilated mice, rats, and dogs after large single bolus intravenous doses of remifentanil. In these studies, the most sensitive species, the male rat, survived following administration of 5 mg/kg.
Intracranial bleedings in dogs caused by hypoxia declined within 14 days after stopping remifentanil application.
\*\*Chronic toxicity\*\*
Bolus doses of remifentanil administered to non-ventilated rats and dogs resulted in respiratory depression in all dose groups, and in reversible intracranial bleedings in dogs. Subsequent investigations showed that the microhaemorrhages resulted from hypoxia and were not specific to remifentanil. Brain microhaemorrhages were not observed in infusion studies in non-ventilated rats and dogs because these studies were conducted at doses that did not cause severe respiratory depression.
It can be inferred from preclinical studies that respiratory depression and associated sequelae are the most likely cause of potentially serious adverse events in humans.
Intrathecal administration to dogs of the glycine formulation alone (i.e. without remifentanil) evoked agitation, pain and hind limb dysfunction and incoordination. These effects are believed to be secondary to the glycine excipient. Because of the better buffering properties of blood, the more rapid dilution, and the low glycine concentration of the Remifentanil formulation, this finding has no clinical relevance for intravenous administration of Remifentanil.
\*\*Reproductive toxicity studies\*\*
Placental transfer studies in rats and rabbits showed that pups are exposed to remifentanil and/or its metabolites during growth and development. Remifentanil-related material is transferred to the milk of lactating rats.
Remifentanil has been shown to reduce fertility in male rats when tested after at least 70 days of daily IV administration of 0.5 mg/kg, which is approximately 0.2 times a human intravenous infusion of an induction dose of 1 microgram/kg with a maintenance dose of 2 micrograms/kg in terms of mg/m2 of body surface area for a surgical procedure lasting 3 hours \*\*or\*\* 40 times a single bolus human dose of 2 micrograms/kg, in terms of mg/m2 of body surface area.
The fertility of female rats was not affected at IV doses up to 1 mg/kg which is 0.4 times a human intravenous infusion of an induction dose of 1 microgram/kg with a maintenance dose of 2 micrograms/kg/min in terms of mg/m2 of body surface area for a surgical procedure lasting 3 hours or approximately 80 times a single bolus human dose of 2 micrograms/kg, in terms of mg/m2 of body surface area, when administered for at least 15 days prior to mating.
No teratogenic effects have been observed with remifentanil at doses up to 5 mg/kg in rats and 0.8 mg/kg in rabbits. Administration of remifentanil to rats throughout late gestation and lactation at doses up to 5 mg/kg IV had no significant effect on the survival, development, or reproductive performance of the F1 generation.
\*\*Genotoxicity\*\*
Remifentanil did not yield positive findings in a series of \*in vitro\* and \*in vivo\* genotoxicity tests, except in the \*in vitro\* mouse lymphoma tk assay, which gave a positive result with metabolic activation. Since the mouse lymphoma results could not be confirmed in further \*in vitro\* and \*in vivo\* tests, treatment with remifentanil is not considered to pose a genotoxic hazard to patients.
\*\*Carcinogenicity\*\*
Long term animal carcinogenicity studies have not been performed with remifentanil.
## Pharmaceutical Particulars
6.1 List of excipients
Glycine
Hydrochloric acid (for pH-adjustment)6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
Remifentanil should not be admixed with Lactated Ringer's Injection or Lactated Ringer's and glucose 50 mg/ml (5 %) solution for injection.
Remifentanil should not be mixed with propofol in the same intravenous admixture solution. For compatibility when given into a running i.v. catheter, please see section 6.6.
Administration of Remifentanil into the same intravenous line with blood/serum/plasma is not recommended as non-specific esterase in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.
Remifentanil should not be mixed with other therapeutic medicinal products prior to administration.6.3 Shelf life
2 years
\*After reconstitution/dilution:\*
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
Do not store above 25°C.
For storage conditions after reconstitution/dilution of the medicinal product, see section 6.3.6.5 Nature and contents of container
10 ml vial of colourless type I glass with bromobutyl rubber stopper and cap
Pack size: 5 vials per pack
Not all pack sizes may be marketed6.6 Special precautions for disposal and other handling
\*\*Reconstitution:\*\*
Remifentanil should be prepared for intravenous use by adding the appropriate volume (as stated in the table below) of one of the below listed diluents to give a reconstituted solution with a concentration of approximately 1mg/ml.
| | | |
| --- | --- | --- |
| \*\*Presentation\*\* | \*\*Volume of diluent to be added\*\* | \*\*Concentration of the reconstituted solution\*\* |
| Remifentanil 1 mg | 1 ml | 1 mg/ml |
| Remifentanil 2 mg | 2 ml | 1 mg/ml |
| Remifentanil 5 mg | 5 ml | 1 mg/ml |
Shake until completely dissolved. The reconstituted solution should be clear, colourless and free of visible particles.
\*\*Further Dilution:\*\*
After reconstitution, Remifentanil must not be used without further dilution to concentrations of 20 to 250 micrograms/ml with one of the injection solutions listed below (50 micrograms/ml is the recommended dilution for adults and 20 to 25 micrograms/ml for paediatric patients aged 1 year and over).
For target-controlled infusion (TCI) the recommended dilution of Remifentanil is 20 to 50 micrograms/ml.
The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.
One of the following solutions should be used for dilution:
• Water for Injections
• Glucose 50 mg/ml (5 %) solution for injection
• Glucose 50 mg/ml (5 %) solution for injection and sodium chloride 9 mg/ml (0.9 %) solution for injection
• Sodium chloride 9 mg/ml (0.9 %) solution for injection
• Sodium chloride 4.5 mg/ml (0.45 %) solution for injection
The following intravenous fluids may also be used when administered into a running IV catheter:
• Lactated Ringer's Injection
• Lactated Ringer's and glucose 50 mg/ml (5 %) solution for injection
Remifentanil is compatible with propofol when administered into a running IV catheter.
No other diluents should be used.
The solution is to be inspected visually for particulate matter prior to administration. The solution should only be used if the solution is clear and free from particles.
Ideally, intravenous infusions of Remifentanil should be prepared at the time of administration (see section 6.3).
The content of the vial is for single use only.
Any unused product or waste material should be disposed of in accordance with local requirements.
